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SUMMARY 
 
Chlamydia pneumoniae can cause acute respiratory infections including pneumonia. 
Repeated and persistent Chlamydia infections occur and persistent C. pneumoniae 
infection may have a role in the pathogenesis of atherosclerosis and coronary heart disease 
and may also contribute to the development of chronic inflammatory lung diseases like 
chronic obstructive pulmonary disease (COPD) and asthma. In this thesis in vitro models 
for persistent C. pneumoniae infection were established in epithelial and 
monocyte/macrophage cell lines. Expression of host cell genes in the persistent C. 
pneumoniae infection model of epithelial cells was studied by microarray and RT-PCR. In 
the monocyte/macrophage infection model expression of selected C. pneumoniae genes 
were studied by RT-PCR and immunofluorescence microscopy. 
 
Chlamydia is able to modulate host cell gene expression and apoptosis of host cells, which 
may assist Chlamydia to evade the host cells’ immune responses. This, in turn, may lead 
to extended survival of the organism inside epithelial cells and promote the development 
of persistent infection. To simulate persistent C. pneumoniae infection in vivo, we set up a 
persistent infection model exposing the HL cell cultures to IFN-γ. When HL cell cultures 
were treated with moderate concentration of IFN-γ, the replication of C. pneumoniae DNA 
was unaffected while differentiation into infectious elementary bodies (EB) was strongly 
inhibited. By transmission electron microscopy small atypical inclusions were identified in 
IFN-γ treated cultures. No second cycle of infection was observed in cells exposed to IFN-
γ , whereas C. pneumoniae was able to undergo a second cycle of infection in unexposed 
HL cells. Although monocytic cells can naturally restrict chlamydial growth, IFN-γ further 
reduced production of infectious C. pneumoniae in Mono Mac 6 cells. Under both studied 
conditions no second cycle of infection could be detected in monocytic cell line 
suggesting persistent infection in these cells.  
 
As a step toward understanding the role of host genes in the development and 
pathogenesis of persistent C. pneumoniae infection, modulation of host cell gene 
expression during IFN-γ induced persistent infection was examined and compared to that 
seen during active C. pneumoniae infection or IFN-γ treatment. Total RNA was collected 
at 6 to 150 h after infection of an epithelial cell line (HL) and analyzed by a cDNA array 
(available at that time) representing approximately 4000 human transcripts. In initial 
analysis 250 of the 4000 genes were identified as differentially expressed upon active and 
persistent chlamydial infection and IFN-γ treatment. In persistent infection more potent 
up-regulation of many genes was observed in IFN-γ induced persistent infection than in 
active infection or in IFN-γ treated cell cultures. Also sustained up-regulation was 
observed for some genes. In addition, we could identify nine host cell genes whose 
transcription was specifically altered during the IFN-γ induced persistent C. pneumoniae 
infection. Strongest up-regulation in persistent infection in relation to controls was 
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identified for insulin like growth factor binding protein 6, interferon-stimulated protein 15 
kDa, cyclin D1 and interleukin 7 receptor. These results suggest that during persistent 
infection, C. pneumoniae reprograms the host transcriptional machinery regulating a 
variety of cellular processes including adhesion, cell cycle regulation, growth and 
inflammatory response, all of which may play important roles in the pathogenesis of 
persistent C. pneumoniae infection. 
 
C. pneumoniae DNA can be detected in peripheral blood mononuclear cells indicating that 
the bacterium can also infect monocytic cells in vivo and thereby monocytes can assist the 
spread of infection from the lungs to other anatomical sites. Persistent infection 
established at these sites could promote inflammation and enhance pathology. Thus, the 
mononuclear cells are in a strategic position in the development of persistent infection. To 
investigate the intracellular replication and fate of C. pneumoniae in mononuclear cells we 
analyzed the transcription of 11 C. pneumoniae genes in Mono Mac 6 cells during 
infection by real time RT-PCR. Our results suggest that the transcriptional profile of the 
studied genes in monocytes is different from that seen in epithelial cells and that IFN-γ has 
a less significant effect on C. pneumoniae transcription in monocytes. Furthermore, our 
study shows that type III secretion system (T3SS) related genes are transcribed and that 
Chlamydia possesses a functional T3SS during infection in monocytes. Since C. 
pneumoniae infection in monocytes has been implicated to have reduced antibiotic 
susceptibility, this creates opportunities for novel therapeutics targeting T3SS in the 
management of chlamydial infection in monocytes. 
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1. INTRODUCTION 
 
Chlamydiales are obligate intracellular bacteria that infect a broad spectrum of 
multicellular and unicellular organisms. Chlamydiae share a unique biphasic 
developmental cycle where the bacteria multiply inside a phagosomal vesicle called 
inclusion. During the developmental cycle, chlamydiae alternate between infectious, 
elementary body (EB) that has been considered metabolically inactive (Haider et al., 
2010), and noninfectious, metabolically active reticulate body (RB).  Chlamydiae are 
among the most successful bacterial pathogens infecting humans and may be responsible 
for a wide range of acute and chronic diseases of significant clinical and public health 
importance.  Chlamydia trachomatis causes ocular infections which can lead to blindness 
(trachoma) and genital infections which can affect female reproductive health (Grayston 
and Wang 1975, Cates and Wasserheit 1991, Paavonen and Lehtinen, 1996). Chlamydia 
pneumoniae causes acute respiratory infections including pneumonia. Repeated and 
persistent Chlamydia infections occur and persistent C. pneumoniae infection may have a 
role in the pathogenesis of atherosclerosis and coronary heart disease (Saikku et al., 1988, 
Saikku et al., 1992b, Melnick et al., 1993) and may also contribute to the development of 
chronic inflammatory lung diseases like chronic obstructive pulmonary disease (COPD) 
and asthma (Hahn et al., 1991, von Hertzen et al., 1999, von Hertzen et al., 2002). C. 
pneumoniae can infect immune cells including monocyte/macrophages in vitro and C. 
pneumoniae DNA has been detected in peripheral blood mononuclear cells from patients 
with cardiovascular disease and from blood donors (Boman et al., 1998, Maass et al., 
2000b, Beagley et al., 2009). It is likely that C. pneumoniae uses monocytes as a means of 
transport from the initial site of infection to the site of chronic inflammatory disease. 
 
Chlamydial persistence is defined as a viable but noncultivable growth stage resulting in a 
long-term relationship with the infected host cell (Beatty et al., 1994a). In vitro persistent 
chlamydial infection can be induced by nutrient and iron depletion or by exposure to 
certain antibiotics or cytokines (Clark et al., 1982, Coles et al., 1993, Beatty et al., 1993, 
Al-Younes et al., 2001). Spontaneous development of a persistent infection in cell culture 
without external induction has also been described (Moulder et al., 1980, Kutlin et al., 
1999). Furthermore, chlamydial infection in monocyte/macrophage cultures has the 
appearance of a persistent infection (Beagley et al., 2009) and circulating monocytes 
carrying C. pneumoniae may have reduced antibiotic susceptibility (Gieffers et al., 2001).  
Although the molecular and cellular mechanisms allowing the development of persistent 
infections are not yet fully understood, genome sequencing and new methods such as 
quantitative PCR, microarray and proteomic profiling have significantly increased our 
knowledge of Chlamydia host cell interactions in recent years, revealing potential markers 
of persistent chlamydial infection and molecules for putative new drug targets.  
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2. CHLAMYDIAE 
 
The Chlamydiae are a group of obligate intracellular bacteria with a broad host range that 
share a developmental cycle characteristic for all Chlamydiae. To accommodate newly 
discovered chlamydia-like organisms new families have been introduced into the phylum. 
In addition to the family Chlamydiaceae, three new families Parachlamydiaceae, 
Simkaniaceae and Waddliaceae have been introduced and at the present systematics order 
Chlamydiales contains four families, 6 genera and 13 species (Everett et al., 1999, 
Rurangirwa et al., 1999). In the original classification order Chlamydiales contained one 
family Chlamydiaceae and one genus Chlamydia. Based on differences in 16S and 23S 
rRNA gene sequences, in 1999 Everett et al. proposed splitting of the family 
Chlamydiaceae into two genera: Chlamydia and Chlamydophila. The genus Chlamydia 
(“trachomatis group”) consists of 3 species and Chlamydophila (“psittaci group”) consist 
of 6 species including 3 new species derived from C. psittaci: C. abortus, C. caviae and C. 
felis (Everett et al., 1999). The new taxonomy and especially the reorganization of 
Chalmydiaceae into two genera is not universally accepted (Schachter et al., 2001, 
Stephens et al., 2009). Since new knowledge of chlamydial genomes and shared biological 
properties between proposed Chlamydia and Chlamydophila genera are in favor of a 
single genus model, in this thesis the one-genus, multiple species nomenclature proposed 
by Stephens in 2009 is used (Stephens et al., 2009) (Table 1.). The best known human and 
animal pathogens are in the family Chlamydiaceae. C. trachomatis is an important 
pathogen causing sexually transmitted diseases worldwide and trachoma in developing 
countries while C. pneumoniae is a wide spread respiratory pathogen, also implicated in 
some chronic diseases. C. psittaci causes avian chlamydiosis and may occasionally spread 
to human causing psittacosis. The other Chlamydia species are mainly veterinary 
pathogens infecting birds, cats, sheep, cattle, pigs, koalas, mice, and guinea pigs (Table 
1.). 
 
2.1 Chlamydia pneumoniae 
 
Originally chlamydiae were thought to be viruses or intermediate organisims with 
properties from both viruses and bacteria. Based on e.g. cell division, cell wall structure, 
DNA-composition, folate synthesis and  the presence of ribosomes with antibiotic 
susceptibilities characteristic of procaryotic ribosomes, Moulder demonstrated the 
definitive bacterial nature of chlamydiae in 1966 (Moulder, 1966) and shortly after, the 
genus Chlamydia was established (Page, 1966) and then divided into two species: 
Chlamydia trachomatis and Chlamydia psittaci (Page, 1968). C. pneumoniae was first 
isolated in 1965 from the conjunctiva of a Taiwanese child (TW-183 strain) participating 
in trachoma study (Kuo et al., 1986), and at that time the isolate was thought to be a strain 
of C. trachomatis. In 1971, when cell culture methods were available the organism (T183) 
was observed by inclusion morphology to resemble more C. psittaci than C. trachomatis 
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(Kuo et al., 1995). The TW-183 strain was associated to pneumonia by serologic evidence 
(Saikku et al., 1985) and this lead to isolation of the first respiratory isolate (AR-39) in 
Seattle 1983 (Grayston et al., 1986). Derived from the first conjunctival and respiratory 
isolates (TW-183 and AR-39) the strain was named TWAR.  In 1989, the establishment of 
a third species in the genus Chlamydia, called Chlamydia pneumoniae was proposed 
(Grayston et al., 1989). 
 
2.1.1. Structure 
 
Chlamydia is classified as gram-negative bacteria and the structure of the chlamydial cell 
wall resembles that of other gram-negative bacteria. A chlamydial cell has two distinctive 
forms: the smaller (∅ ~0,3 µm) “more tightly” packed elementary body (EB) adapted for 
extracellular survival and  larger (∅ ~1 µm) vegetative intracellular reticulate body (RB), 
which is believed to divide by binary fission. Both forms have inner and outer membranes 
with a periplasmic space in between (Figure 1.). The extracellular EB form of Chlamydia 
has been thought to be metabolically inactive. However, in a recent study some protein 
production was shown for extracellular EB when incubated in growth media providing 
nutrients (Haider et al., 2010). Unlike the other gram-negative bacteria, Chlamydia seems 
to lack detectable amounts of peptidoglycan in the periplasm (Fox et al., 1990). Still 
Chlamydia has genes for peptidoglycan synthesis and is at least partially sensitive to 
penicillin (Moulder, 1993, Rockey et al., 2000). Peptidoglycan usually provides rigidity to 
bacterial cell walls, but in chlamydial EB the cell wall rigidity has been proposed to be 
due to cross-linked disulfide bonds between the proteins of outer membrane complex 
(OMC) (Hatch, 1996). The OMC consist mainly of major outer membrane protein 
(MOMP), outer membrane protein 2 (omp 2), outer membrane protein 3 (omp 3), and 
polymorphic membrane proteins (pmp). Typically gram-negative bacteria have 
lipopolysaccharide (LPS) on the outer membrane that functions as an endotoxin. 
Chlamydial LPS is similar to the rough forms of enterobacterial LPS and consists of the 
lipid A and core polysaccharide moieties. Also in Chlamydia the LPS is localized on the 
surface (Birkelund et al., 1989), yet the endotoxin activity of chlamydial LPS is much 
lower than that of enterobacteria (Nurminen et al., 1983, Ingalls et al., 1995, Heine et al., 
2003). This reduced activity may be due to the unusual structure of chlamydial lipid A, 
which contains a reduced number of fatty acids and an enlarged hydrophobic domain 
(Kosma, 1999). It has recently been suggested that the lower potency of chlamydial LPS 
may be due to its lower binding affinity to LPS recognizing molecules such as LPS 
binding protein and CD14 (Tsutsumi-Ishii et al., 2008). 
 
 
 
13 
 
Table 1. Taxonomy of Chlamydiae, modified from Beagley et al., 2009 
Systematics Natural host Pathogenicity 
Order Chlamydiales   
Family I: Chlamydiaceae   
  Genus I: Chlamydia   
       C. trachomatis Humans Ocular, urogenital infections 
       C. pneumoniae Humans, horses, koalas Respiratory, ocular, urogenital infections 
       C. muridarum Rodents Respiratory, ocular, urogenital infections 
       C. suis Swine Enteritis 
       C. psittaci Birds Avian chlamydiosis 
       C. abortus Ruminants Abortion 
       C. pecorum Cattle, sheep, koalas Enteritis, abortion, polyarthritis, ocular, 
urogenital infections 
       C. felis Cats Ocular, respiratory infections 
       C. caviae Guinea pigs Ocular, urogenital infections 
Family II: Parachlamydiaceae   
  Genus I: Parachlamydia   
      P. acanthamoebae Acanthamoeba Endosymbiont 
  Genus II: Neochlamydia   
      N. hartmannellae Hartmannella Parasite 
Family III: Simkaniaceae   
  Genus I: Simkania   
       S. negevensis Humans (?) Respiratory infections (?) 
  Genus II: Fritschea   
      F. bemisiae Insects  
      F. eriococci Insects  
  Genus III: Rhabdochlamydia   
       R. crassificansa Woodlice Hepatopancreas 
       R. porcellionisb Cockroach Abdominal swelling 
Family IV: Waddliaceae   
  Genus I: Waddlia   
      W. chrondrophila Cattle (?), fruit bats (?) Abortion (?) 
a Kostanjsek et al., 2004   
b Corsaro et al., 2007   
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2.1.2 Genome 
 
The chlamydial nucleoid apparent in the EB form of Chlamydia (Figure 1.) consists of the 
chromosome and two eukaryotic histone-like proteins Hc1 and Hc2. The Hc-proteins are 
involved in the nucleoid condensation and in the regulation of chlamydial gene expression 
(Hackstadt et al., 1991, Hackstadt et al., 1993, Pedersen et al., 1994, Pedersen et al., 
1996).  C. pneumoniae has a small genome of ~1.23 x 106 base pairs (bp). The small 
genome results probably from reductive evolution during which Chlamydia has gradually 
dispensed the unessential genes in the process of adapting to intracellular environment 
(Bavoil et al., 2000). The genome of C. pneumoniae is slightly larger than that of C. 
trachomatis. When compared to the C. trachomatis genome, C. pneumoniae has additional 
214 coding sequences. Only few of the additional coding sequences are homologous to 
genes from other organisms. The major functionally known addition to C. pneumoniae 
genome is a large expansion of genes coding pmps. C. pneumoniae genome contains 
genes for 21 pmps while C. trachomatis has only 9. There are also a few genes that C. 
trachomatis codes but that are missing from the genome of C. pneumoniae. The most 
important of these are perhaps the genes of the tryptophan biosynthesis operon, which 
may affect the ability of Chlamydia to persist in their hosts (Kalman et al., 1999). C. 
pneumoniae differs also from C. trachomatis in respect of extra chromosal DNA elements: 
C. pneumoniae does not harbor a plasmid like C. trachomatis does, but a single stranded 
DNA bacteriophage φCpn1 has been found in some C. pneumoniae strains and all strains 
may be susceptible for φCpn1 infection (Read et al., 2000, Karunakaran et al., 2002, Rupp 
et al., 2007). Up to date genome sequences of at least five C. pneumoniae strains have 
been completed including human isolates AR39, CWL029, TW183, and J138 (GenBank 
accession numbers: AE002161, AE001363, AE009440 and BA000008, respectively) and 
a koala isolate LPCoLN (GenBank accession number CP001713). Only slight differences 
have been found between the different human C. pneumoniae strains (Shirai et al., 2000a, 
2000b, Vandahl et al., 2004). However, the koala C. pneumoniae, which has a slightly 
larger genome than the human strains, seems to represent an “older” C. pneumoniae strain, 
retaining some functions that have been lost or fragmented during evolution in human 
strains (Myers et al., 2009, Mitchell et al., 2010).    
EB RB
 
Figure 1. Electron microscopic image of Chlamydia pneumoniae EB and RB. Note the electron dense 
(black) nucleoid apparent in the EB. 
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The lack of suitable methods for genetic manipulation of the Chlamydia genome has made 
it very difficult to study the functions of individual genes. Even though some progress has 
been made in recent years, the ability to manipulate the chlamydial genome remains a key 
challenge. However, there is hope that the identified bacteriophages capable to infect C. 
pneumoniae offer a vector for delivering foreign DNA into C. pneumoniae in the future. 
 
2.1.3. Developmental cycle 
 
The C. pneumoniae infection is initiated by attachment of EB to the cell surface and the 
EB are rapidly internalized by the host cell. Chlamydia uses several mechanisms to enter 
the host cell, including receptor-mediated endocytosis in clathrin coated pits, pinocytosis 
in non-clathrin coated pits and phagocytosis. There are probably also multiple mechanisms 
for attachment and internalization and these mechanisms are likely chlamydia species 
and/or host cell type dependent (Wyrick, 2000, Puolakkainen et al., 2005). Association of 
Chlamydia with lipid rafts and/or actin-rich pedestrials have been described to facilitate 
chlamydial entry and a putative T3S-effector protein TARP (translocated acting recruiting 
phosphoprotein) homolog has been shown to recruit actin to the entry site (Clifton et al., 
2004, Dautry-Varsat et al., 2005,  Jewett et al., 2010). Several bacterial molecules, such as 
glucosaminoglycan, MOMP, Omp2, Hsp70, and Pmps have been proposed as ligands or 
adhesins mediating the attachment (Zhang and Stephens, 1992, Raulston et al., 1993, Su et 
al., 1996, Wehrl et al., 2004a, Fadel et al., 2007, Mölleken et al., 2010) and for cellular 
receptors of EB such molecules as heparan sulfate, mannose receptor, mannose 6-
phosphate/insulin like growth factor 2 receptor and estrogen receptor have been suggested 
(Kuo et al., 2002, Davis et al., 2002, Puolakkainen et al., 2005). In addition, recent 
microarray and RNAi studies have revealed several additional host cell molecules 
important in chlamydial entry (Elwell et al., 2008, Wang et al., 2010).  
 
Transcription and translation are initiated rapidly after infection. The trigger for the 
initiation of transcription is unknown, but it may happen already upon attachment. The 
internalized EB containing phagosome resists fusion with lysosomes, which is dependent 
on chlamydial gene transcription and translation (Scidmore et al., 1996). Inside the 
phagosome, EB transform rapidly into RB which start to replicate their genomes inside the 
phagosomal inclusion. The inclusion exits soon from the endocytic pathway, enters into 
the exocytic pathway and the inclusion is transported to perinuclear region. To 
accommodate multiplying bacteria the developing inclusion must expand and the 
inclusion membrane grows by acquisition of lipids derived from the host cell (Hackstadt et 
al., 1995, Hackstadt et al., 1996, Wylie et al., 1997). One source of the lipids is the Golgi 
apparatus, which is abundant in the perinuclear region (Hacksadt et al., 1996, Heuer et al., 
2009). A network of host cell cytoskeletal structures primarily composed of F-actin and 
intermediate filaments (IFs) provide structural stability for the inclusion during 
development (Kumar and Valdivia, 2008).  During active productive infection, RB-forms 
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are thought to divide by binary fission, whereas it is typical for a persistent infection that 
this stage is impaired. In persistent infection the replication of the DNA seems apparently 
normal, but division of the bacteria is inhibited resulting in aberrant RB-forms (AB) 
observed by electron microscopy (Beatty et al., 1993, Byrne et al., 2001). In active
infection, after multiplication, RB transform to EB and exit the cell either by cell lysis or 
inclusion extrusion ready to initiate new cycle of infection (Hybiske and Stephens, 2007), 
while in persistent infection the immature inclusions persists (Figure 2.).
Attachment and entry Inhibition of 
phagolysosomal fusion
EB transforms to RB
Division by binary fission
RB transform 
to EB
Exit
Persistent inclusion with AB
Mature inclusion
N NN
N
N N
 
Figure 2. Schematic presentation of the chlamydial developmental cycle. N= nucleus, AB= aberrant body.
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2.1.4. Regulation of gene expression 
 
In order to survive the bacterium needs to monitor its surroundings and adjust gene 
expression accordingly. The gene expression can be regulated at a transcriptional level, 
post-transcriptional level, translational level or post-translational level. Bacterial 
development is largely regulated at the level of transcription, mediated by both activators 
and repressors. In bacterial chromosomes a transcriptional unit consists of a regulatory 
region, a transcription start site, one or more open reading frames, and a transcription 
termination site. The regulatory region contains such elements as the promoter, where the 
RNA polymerase initially binds, and transcription factors binding sites, where 
transcription factors bind to modulate the binding of the RNA polymerase. Transcription 
initiation in bacteria requires proteins known as sigma factors (σ), which are essential for 
proper promoter recognition by RNA polymerase. Bacteria can have multiple σ factors 
enabling transcription initiation from different promoters (Balleza et al., 2009).  In 
addition to regulation of initiation of transcription by different promoters, sigma factors 
and transcription factors, also DNA accessibility affects transcription. Compactness of the 
DNA might represent a physical constraint to transcription initiation and the packing of 
some chromosomal regions depends on the activity of several proteins such as integration 
host factor (DNA bending protein), histone like proteins, DNA isomerases, DNA 
chaperones, and accessory proteins (Balleza et al., 2009). Also alternate mRNA folding 
and mRNA stability affects whether or not the RNA molecule is translated. Recently small 
regulatory non-coding RNAs have been reported to attenuate transcription. In addition, 
mRNA can act as a direct sensor of small molecules and binding of the molecule directs 
the RNA to fold differently, preventing translation or the bound molecule may trigger 
cleavage of the RNA molecule by ribozyme activity (Brantl, 2004).   
 
Large-scale analyses of chlamydial gene expression have showed that the genes are 
transcribed coordinately in a temporal fashion (Shaw et al., 2000, Belland et al., 2003a, 
Nicholson et al., 2003, Ouellette et al., 2006, Mäurer et al., 2007). Three stages of 
transcription have been identified: 1) The early expressed genes initiate macromolecular 
synthesis and potentially modify the bacterial phagosome enabling it to escape fusion with 
lysosymes. Among the early expressed genes are euo and inclusion membrane proteins 
(Wichlan and Hatch, 1993, Shaw et al., 2000, Belland et al., 2003a). 2) The mid cycle 
expressed genes represent the metabolically most active stage when chlamydial genomes 
replicate and cells divide. Indeed, at this stage Belland et al. noticed that almost all genes 
were transcribed, thus highlighting the small facultative capacity of the chlamydial 
genome (Belland et al., 2003a). 3) The genes expressed at late cycle represent transition of 
RB to EB and accordingly, cystein-rich membrane proteins omp2 and omp3 involved in 
EB maturation and histone like proteins Hc1 and Hc2 mediating the condensation of the 
chromosome are up regulated at this stage (Belland et al., 2003a, Nicholson et al., 2003, 
Mäurer et al., 2003). Based on the transcription profiles also the type III secretion 
apparatus seems to be assembled late in the developmental cycle of Chlamydia and likely 
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arms the forming EB to confront the new host cell (Nicholson et al., 2003, Mäurer et al., 
2007). In addition to early, mid and late cycle genes Mäurer et al. identified a fourth 
temporal class, which they named tardy. Tardy genes are expressed very late at the 
developmental cycle and the gene transcripts are suggested to represent mRNA packed in 
the EB (Mäurer et al., 2007). 
 
It seems that the temporal expression of the chlamydial genes is well coordinated and the 
genes are transcribed only at the time they are needed. However, relatively little is known 
about the regulation of transcription. Genomic sequencing has shown that Chlamydia has 
three different sigma factors σ28, σ54, and σ66 (Stephens et al., 1998, Kalman et al., 1999) 
and they are expressed in a temporal fashion (Mathews et al., 1999). The σ66 is the major 
sigma factor while σ54 and σ28 allow alternate promoter identification.  The σ28 have been 
proposed to be a stage specific regulator of late genes (Yu et al., 2006), but not all genes 
under σ28 regulation have late gene profile (Mäurer et al., 2007) and some of the late 
genes are under σ66 regulation (Fahr et al., 1995), supporting earlier observation that it is 
unlikely that the major role of chlamydial sigma factors is to recognize the promoters of 
stage-speciﬁc genes (Douglas and Hatch, 2000).  
 
Schaumburg and Tan have suggested that chlamydial promoters may be intrinsically weak 
to allow transcription factors to regulate the complexity of chlamydial growth and 
development (Schaumburg and Tan, 2003). Several transcription factors have been 
identified for Chlamydia including both activators (Zhong et al., 2001b, Koo et al., 2006, 
Hickey et al., 2011) and repressors (Wyllie and Raulston, 2001, Wilson and Tan, 2002, 
Wood et al., 2003). Also the DNA structure plays a role in the regulation of chlamydial 
gene transcription, and integration host factor and histone like proteins are likely involved 
in the accessibility of a gene or its promoter for transcription (Mathews and Stephens 
1999, Niehus et al., 2008). Recently, Niehus et al. demonstrated that individual 
chlamydial promoters show a differential response to changes in DNA supercoiling that 
correlates with the temporal expression pattern. This suggests a role for DNA structure in 
the regulation of the global patterns of temporal gene expression (Niehus et al., 2008). 
Like in other bacteria, some recent reports indicate a role for small non-coding RNAs in 
the regulation of chlamydial transcription (Grieshaber et al., 2006a, 2006b, AbdelRahman 
et al., 2010, Albrecht et al., 2010). 
 
2.1.5. Interaction with the host cell 
 
In order to efficiently infect and colonize their eukaryotic hosts, bacteria have evolved 
specialized secretion mechanisms to transport their proteins to the extracellular space or to 
the host cell compartments. Gram-negative bacteria possess several different secretion 
systems (Table 2.).  
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Table 2. Protein export, secretion and translocation systems in gram-negative bacteria, 
systems indicated in Chlamydiae are in bold, adapted from Beeckman and Vanrompay, 
2010 
Name Process Sec/Tat  dependence Remarks 
Sec and Tat Exporta NA  
T1SS Secretionb No  
T2SS Secretion Yes  
T3SS Translocationc No  
Flagellum Secretion No Equivalent to T3SS 
T4SS Translocation Variable Conjugation system 
T4P Secretion Yes Equivalent to T2SS 
T5SS Secretion Yes  
T6SS Translocation No  
C/U Secretion Yes Assembly of pili and fimbriae 
a Export refers to transport of unfolded and/or folded proteins to the periplasmic space 
b Secretion refers to transport of proteins to or across the bacterial surface 
c Translocation refers to the transport of proteins directly across the eukaryotic cell membrane into the 
host cell cytoplasm 
Sec = Sec pathway   
Tat = Twin-arginine translocation 
pathway   
T1-6SS = Type 1-6 secretion system   
T4P = Type IV pili    
C/U = Chaperone/usher pathway   
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In Chlamydia Sec-dependent, Type III and Type V (autotransporter pathway) associated 
secretion has been identified (Subtil et al., 2001, Jorgensen and Valdivia, 2008, Chen et 
al., 2010). In addition, Chlamydia possesses significant, but incomplete number of type II 
core proteins (Peabody et al., 2003) and active type II secretion has been implicated (Betts 
et al., 2009, Zhong et al., 2010). Many pathogenic gram-negative bacteria modulate host 
cell responses via type III secretion system by injecting specific effector molecules to the 
host cell cytoplasm. Over 20 years ago “surface projections” resembling morphologically 
the Salmonella typhimurium type III apparatus were identified on Chlamydia (Matsumoto 
et al, 1976, Matsumoto, 1981, Nichols et al., 1985) and 10 years later genes for type III 
secretion system were revealed in chlamydial genome (Hsia et al., 1997, Stephens et al., 
1998). However, the genome sequence data demonstrated that Chlamydiae encode a 
reduced collection of proteins involved in the secretory machine (Rockey et al., 2000). 
Several putative C. pneumoniae effector proteins secreted into the host cell cytosol and 
nucleus have been identified (Table 3.) and these effectors are likely important virulence 
factors for Chlamydia. Chlamydiae also produce proteins that are inserted into the 
inclusion membrane and at least some of them are T3S secreted (Table 3.). Inclusion 
membrane protein (Inc) A was the first protein demonstrated to be localized to the 
inclusion membrane (Rockey at al., 1995). And since then over 40 candidates of Inc 
proteins have been identified in the chlamydiae genome. The Inc proteins share little 
sequence homology, but they share a unique bilobed hydrophobic domain suggesting 
structural homology (Bannantine et al., 2000). Based on their location in the inclusion 
membrane Incs are likely to play important role in the interaction between Chlamydia and 
the host cell. IncA has been shown to be required for homotypic fusion in C. trachomatis 
inclusions and C. trachomatis Inc G has been implicated to interact with host cell 
signaling pathways (Hackstadt et al., 1999, Scidmore and Hackstadt, 2001). An inclusion 
membrane protein of C. pneumoniae (Cpn0585) has been suggested to interact with host 
Rab GTP:ases, which are involved in the generation, transport, docking, and fusion of 
vesicles, as well as in many other membrane trafﬁcking functions. Interestingly, 
overexpression of Cpn0585 in HEp-2 cells led to restricted C. pneumoniae infection 
resembling persistent infection (Cortes et al., 2007).    
 
The Th1 type immune response and production of gamma interferon (IFN-γ) are critical 
for eradication of chlamydial infection (Johansson et al., 1997, Penttilä et al., 1998). 
Given the importance of the Th1-biased cellular immune response for protection, it is 
significant that Chlamydia seem to have developed specific immunoevasion strategies. 
Chlamydia can inhibit the expression of major histocompatibility complex (MHC) II 
antigen by degradation of the upstream stimulatory factor-1 (USF-1) and the expression of 
MHC class I antigen by degradation of the downstream transcription factor RFX5 (Zhong 
et al., 2000). A secreted chlamydial proteasome-like activity factor (CPAF) is responsible 
for RFX5 and USF-1 degradation (Zhong et al., 2001a, Fan et al., 2002). CAPF is secreted 
across the inner membrane in a Sec-dependent manner and is further transported across 
the outer membrane with an unknown mechanism (Chen et al., 2010). In addition to 
cleaving host cell transcription factors, CPAF is also capable of cleaving host cell IF-
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proteins cytokeratin 8, cytokeratin 18, and vimentin possibly contributing to cytoskeletal 
arrangements seen during chlamydial infections (Kumar and Valdivia 2008, Dong et al., 
2004, Heuer et al., 2003). Another important chlamydial immunoavoidance mechanism 
targets major innate immunity signaling pathways, particularly NFκB. Chlamydia has 
been implicated to reduce cell surface exposure of tumor necrosis factor receptor 1 
(Paland et al., 2008), to modulate other cytokine receptors (Shirey and Carlin 2006, Wolf 
et al., 2009), to inhibit IkBa degradation (Le Negrate et al., 2008) and to specifically 
degrade p65 subunit of NFκB by chlamydial tail-specific protease (Lad et al., 2007a, 
2007b) 
Chlamydia has been reported to both inhibit and induce programmed cell death, apoptosis 
(Fan et al., 1998, Ojcius et al., 1998, Fischer et al., 2001, Airenne et al., 2002, Dean and 
Powers, 2001, Perfettini et al., 2002, Stenner-Liewen et al., 2002, Dumrese et al., 2005). 
Chlamydia prevents apoptosis by inhibiting cytochrome c release from mitochondria. 
Release of cytochrome c is required for activation of caspase 3 and Chlamydia cannot 
resist apoptotic stimuli once caspase 3 has been activated (Fan et al., 1998, Fischer et al., 
2001). Infection of monocytes has been reported to activate NF-κB, which may at least in 
part be responsible of apoptosis inhibition in this cell type (Wahl et al., 2001). Persistent 
Chlamydia infection has been shown also to resist apoptotic stimuli (Dean and Powers, 
2001, Airenne et al., 2002). Airenne et al., showed that during persistent C. pneumoniae 
infection the inhibition of apoptosis was still observed at the end of the follow-up period at 
five days post infection and was restricted to the cells carrying chlamydial inclusions 
(Airenne et al., 2002). Evasion of host cell apoptosis may be an important mechanism for 
C. pneumoniae to establish persistent infection, since active maintenance of host-cell 
viability and longevity would allow a long term relationship between Chlamydia and the 
host cell. On the other hand at the end of the developmental cycle of active infection 
Chlamydia must exit the host cell and induction of apotosis may facilitate the exit, 
although the cell death at the end of developmental cycle may be Chlamydia induced, but 
nonapoptotic (Paschen et al., 2008). A Chlamydial effector protein CADD has been 
reported to induce apoptosis in a variety of mammalian cells via binding to the death 
domains of TNF family receptors (Stenner-Liewen et al., 2002). 
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2.1.6. Chlamydia pneumoniae diseases 
 
C. pneumoniae is a respiratory pathogen and it has been estimated to cover ~10 % of 
community acquired pneumonia and ~5% acute bronchitis and sinuitis cases. However, 
more often C. pneumoniae infection causes common cold or the infection is 
asymptomatic. Cough is common and often prolonged. Incubation period of C. 
pneumoniae infection can be several weeks, which is exceptionally long. Epidemics have 
been reported, and their course is usually long. The organism is thought to spread from 
person to person via respiratory droplets and the spread of infection seems to be relatively 
inefficient (Ekman et al.1993, Kauppinen et al, 1995). C. pneumoniae infection appears to 
be most common with children over 5 years of age. The prevalence of C. pneumoniae 
antibodies increases most from 5 to 14 years of age, and by age 20 approximately 50% are 
seropositive, and the seropositivity reaches approximately 75-80% among the elderly 
(Saikku, 1992a, Kuo et al., 1995). Reinfection with C. pneumoniae appears to be common 
and the acute phase can be followed by a persistent or chronic C. pneumoniae infection 
(Grayston et al., 1990, Saikku, 1992a). Also co-infections occur with other respiratory 
tract pathogens especially with Streptococcus pneumoniae and Mycoplasma pneumoniae 
(Kauppinen et al., 1995, 1996, Heiskanen-Kosma et al., 1999, Monno et al., 2002). 
 
Persistent C. pneumoniae infection may be a major contributor to several common human 
diseases, including atherosclerosis, asthma and even lung cancer. The ability of C. 
pneumoniae to persist and therefore chronically stimulate the immune system with 
bacterial antigens is likely an important biological property of the bacteria contributing to 
the chronic inflammatory process of atherosclerosis (Mahony and Coombes, 2001). 
Atherosclerosis is characterized by persistent inflammation at the vessel wall, overgrowth 
of smooth muscle cells, formation of fibrous scar like-tissue, lipid deposition and intimal 
thickening leading to narrowing of the vessel lumen (Ross, 1999). The first association of 
C. pneumoniae with atherosclerosis was based on the serological land mark study by 
Saikku and his colleagues at 1988 (Saikku et al., 1988). This association is supported by 
several pathological studies. C. pneumoniae genome, proteins and even viable bacteria 
have been identified in atherosclerotic tissues (for more detail see chapter 2.1.7. Cell 
tropism). In mouse and rabbit experimental infection models, repeated intranasal infection 
with C. pneumoniae results in increased aortic lipid accumulation, induction of early 
atherosclerotic lesions or accelerated progression of atherosclerosis (Fong et al., 1997, 
Laitinen et al., 1997, Campbell et al., 2000, Erkkilä et al., 2004, Törmäkangas et al., 
2005a). Recently, Campbell et al., showed in an experimental infection model that the 
expression of scavenger receptor for oxidized low density lipoprotein and proatherogenic 
factors in the lung and aorta of mice are induced by repeated C. pneumoniae infections 
(Campbell et al., 2010). In addition, some data from animal models indicate that 
antibiotics given in the early course of the infection prevent induction or reduce the 
progression of atherosclerosis by C. pneumoniae (Muhlestein et al., 1998, Fong et al., 
2002). However, if the antibiotic is given later, there is much less or no reduction in the 
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progression of atherosclerosis by C. pneumoniae (Rothstein et al., 2001, Fong et al., 
2002). Antibiotic treatment for the prevention of cardiac events in humans has produced 
varied results. However, a number of preliminary clinical trials of antibiotic therapy 
directed at atherosclerotic changes in the carotid artery, peripheral arteries, and the aorta 
have reported favorable effect on the progression of disease. The large clinical trials 
(WIZARD, PROVE-IT, and ACES) studying antibiotic monotherapy for the prevention of 
cardiac events in humans have shown that antibiotic administration cannot be 
recommended for the treatment of chronic coronary heart disease. Yet, antibiotic 
administration may be beneficial for prevention of disease development (Campbell and 
Kuo, 2004, Grayston et al., 2005).  
 
Asthma is a chronic inflammatory disease of the airways and it is characterized by 
bronchial construction, wheezing, breathlessness, chest tightness, and coughing. Along 
with some viruses and M. pneumoniae, C. pnemoniae is associated with initiation, 
exacerbation and promotion of asthma (Hahn, 1996). The pathogenesis of virus associated 
asthma exacerbations has been postulated to involve several mechanisms including 
epithelial damage, release of inflammatory mediators, and generation of virus-specific 
IgE-antibodies (Hahn, 1999). Hahn suggests that some of the mechanisms of virus-
associated asthma also apply to Chlamydia associated asthma: 1) C. pneumoniae infects 
the human bronchial tree causing ciliary dysfunction and epithelial damage. 2) Chlamydia 
generates inflammatory cytokines both in vitro and in vivo 3) C. pneumoniae-specific IgE 
has been associated to asthma in culture positive children and in patients with adult-onset 
asthma. Additional potential mechanisms include C. pneumoniae-induced macrophage 
and/or smooth muscle cell dysregulation and LPS-induced bronchial hyperreactivity 
(Hahn, 1999). 
 
2.1.7. Cell tropism 
 
In addition to a broad host range, C. pneumoniae seems to be able to infect a large variety 
of human cells in vitro. In addition to alveolar epithelial cells, which are primary target 
cells of C. pneumoniae (Rupp et al., 2004), association of C. pneumoniae to numerous 
chronic diseases has lead to setting up experimental infection models and in vitro infection 
models of relevant cell types for the associated diseases (Campbell and Kuo 2004, Dreses-
Werringloer et al., 2006, Beagley et al., 2009).   
 
Typical respiratory epithelium (TRE) consists of ciliated pseudostratiﬁed columnar 
epithelial cells with mucus-producing goblet cells scattered throughout. TRE is the 
characteristic lining epithelium from the nose to the small bronchioles. The alveoli are 
lined by squamous type I epithelium (Type I pneumocytes). Type II pneumocytes are 
typically found at the alveolar-septal junctions and they produce and secrete surfactant, a 
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lipid rich material that coats the inside of the alveoli. Type II pneumocytes have also been 
suggested to significantly contribute to pulmonary inflammation response when exposed 
to endotoxin (Sunil et al., 2002). Also macrophages are present in the alveoli and during 
infection their amount increases greatly as monocytes migrate to the lungs and 
differentiate into macrophages. In an ex vivo model of pulmonary infection, C. 
pneumoniae was detected in similar percentages in type I and type II pneumocytes (~4% 
of cells) by immunohistochemical staining and in situ hybridization (Rupp et al., 2004). In 
contrast, in pulmonary tissues from COPD patients C. pneumoniae was mainly observed 
in type II cells (Rupp et al., 2004). C. pneumoniae was only sporadically detected in TRE 
cells, whereas it was present in ~30% of alveolar macrophages (Rupp et al., 2004).    
 
Monocytes are thought to be the carriers of C. pneumoniae from the initial site of infection 
to the site of inflammatory disease. Indeed, C. pneumoniae can infect peripheral blood 
mononuclear cells (PBMC) and monocyte/macrophage cell lines such as U-973, THP-1 
and Mono Mac 6 (Beagley et al., 2009). In addition, C. pneumoniae DNA has been 
detected in peripheral blood mononuclear cells from patients with cardiovascular disease 
and from blood donors (Beagley et al., 2009, Boman et al., 1998, Maass et al., 2000b) 
suggesting that mononuclear cells are susceptible to C. pneumoniae infection also in vivo. 
Consistently in infection studies with monocyte/macrophages, chlamydial replication is 
limited and it seems that macrophages are more susceptible to chlamydial infection than 
monocytes (Beagley et al., 2009). However, usually while infectious EB cannot be 
isolated from monocyte/macrophages, the bacteria still remains viable inside the cell as 
demonstrated by the presence of bacterial RNA transcripts. In addition to means of 
transport from initial site of infection, infection of macrophages with C. pneumoniae 
seems to enhance adherence and migration of macrophages to endothelial cells (Molestina 
et al., 1999, Kalayoglu et al., 2001, May et al., 2003). C. pneumoniae has also been shown 
to induce low density lipoprotein oxidation and increased uptake of cholesterol by 
macrophages and subsequent foam cell formation (Kalayoglu et al., 1999, Kalayoglu and 
Byrne, 1998). Recently, Bobryshev et al., demonstrated in atherosclerotic tissue samples 
the presence of chlamydial elementary, reticulate, and aberrant body like stuctures in the 
cytoplasm of macrophage foam cells (Bobryshev et al., 2008). 
 
C. pneumoniae can infect also other immune cells in vitro including dendritic cells, 
neutrophils and T-lymphocytes (Haranaga et al., 2001, van Zandbergen et al., 2004, 
Wittkop et al., 2006), and is capable to at least survive and induce inflammatory response 
in mast cells (Oksaharju et al., 2009). Several studies have shown C. pneumoniae antigen 
or DNA in atheromatous plaques (Campbell et al., 1995, Muhlestein et al., 1996, Maass et 
al., 1998b, Bartles et al., 1999) and viable Chlamydia from atherosclerotic coronary and 
caroitid arteries (Ramirez, 1996, Jackson et al., 1997, Maass et al., 1998a). In vitro C. 
pneumoniae has been shown to be capable to infect human endothelial cells, smooth 
muscle cells, and fibroblasts (Kaukoranta-Tolvanen et al., 1994, Godzik et al., 1995, 
Gaydos et al., 1996, Maass et al., 2000a). C. pneumoniae has been identified within 
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astrocytes and microglia in the brain of late-onset alzheimer disease patients (Balin et al., 
1998, Arking et al., 1999) and C. pneumoniae has been isolated from brain samples of 
late-onset alzheimer disease patients (Dreses-Werringloer et al., 2009). In addition, C. 
pneumoniae is capable of productive infection in human astrocytoma and microglioma 
cell lines (Dreses-Werringloer et al., 2006). The capability of C. pneumoniae to infect a 
large variety of cell types is likely an important contributor to its virulence because the 
capacity to induce disease is dependent on the cell and tissue infected. 
 
2.1.8. Immunopathology 
 
Immunopathology is a disease process that has an immunologic cause e.g. injury induced 
by antibodies or other products of an immune response. Tissue damage and scarring seen 
in chlamydial infections (e.g. blinding trachoma and tubal factor infertility associated to C. 
trachomatis infection) are caused by inﬂammation-based pathology and inflammation is a 
key pathologic feature of chronic C. pneumoniae disease associations. Chlamydial 
infection, especially reinfection, evokes an inﬂammatory response in the host and the 
response aims at the clearance of the infection, but it may also lead to immunopathology. 
The immune response to chlamydial infection involves both innate and adaptive immunity 
(Puolakkainen, 2009). The innate immunity offers the first line of defense against 
microbial infections. The innate immune response involves pattern recognition receptors 
(PRR) on the surfaces of immune and non-immune cells. With the aid of these molecules, 
cells sense the invading micro-organism by recognizing specific structures (pathogen 
associated molecular patterns, PAMP) of the invading micro-organism (Puolakkainen, 
2009). In connection to chlamydial infection, toll like receptors 2 (TLR2) and 4 (TLR4) 
are the most studied PRR and several putative PAMP on Chlamydia have been identified 
including LPS and Hsp60 (Puolakkainen, 2009). PRR recognition of PAMP leads to the 
activation of phagocytes and signaling cascades that activate host transcription factors NF-
κB and AP-1 leading to expression of proinflammatory cytokines such as IL-1β, TNF-α 
and IL-6 (Darville, 2006, Puolakkainen, 2009). Although immune cells such as 
macrophages and neutrophils are the key elements of the innate immune system, the 
epithelial cells are the ﬁrst line of defence against the Chlamydia infection. Rasmussen et 
al. were the first to show that epithelial cells secrete proinflammatory cytokines in 
response to chlamydial infection (Rasmussen et al., 1997). Since then others have shown 
the production of inflammatory mediators from non-immune host cells during chlamydial 
infection suggesting that the inflammatory response to Chlamydia is initiated and 
sustained by infected non-immune host cells (Darville, 2006). Persistent C. pneumoniae 
infection may result in constant activation of host cell signaling pathways leading to 
persistent inflammation, and thus contributes to the pathogenesis of a chronic 
inflammatory disease. In contradiction, Chlamydia has also been proposed to disrupt NF-
κB signal transduction and thus the subsequent inflammatory response with the aid of 
chlamydial tail-specific protease. However, it was suggested that it may allow for 
persistent Chlamydia infection to establish in humans and prevent the formation of a long-
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lasting immunity against the infection (Lad et al., 2007a, 2007b), and on the other hand it 
has been suggested that once persistent infection has been established the cells would no 
longer be protected from NF-κB stimulation (Betts et al., 2009). 
 
The cytokines secreted by epithelial cells may also have a role in directing the adaptive 
immune response. The adaptive immune system consists of two arms, humoral immunity 
(B lymphocytes) and cell mediated immunity (T lymphocytes). In adaptive immunity, a 
strong T-cell response is required to eradicate infected cells, whereas humoral immunity 
associated antibody response may neutralize the EB in the extracellular environment. 
However, only partial protection is achieved during natural infection and reinfections are 
common. Two T helper cell subsets are recognized based on their cytokine secretion 
profiles, T helper 1 (Th1) and T helper 2 (Th2). Th1 cells secrete e.g. IFN-γ, IL-2, and 
lymphotoxin, and Th2 cells secrete e.g. IL-4, IL-5, IL-6, and IL-13 (Cherwinski et al., 
1987, Mosmann and Coffman, 1989). Also Th0 pattern, which includes both Th1 and Th2 
cytokines, has been described (Caccamo et al., 2005). The Th1 response and production of 
IFN-γ are critical for eradication of chlamydial infection (Johansson et al., 1997, Penttilä 
et al., 1998), while Th2 response with production of IL-4 and IL-10 may promote 
persistence and pathology (Yang et al., 1996). Indeed, patients with severe trachomatous 
scarring have been shown to elicit Th2 type cytokines (Holland et al., 1996). 
 
There are numerous factors that probably influence the susceptibility to and the severity of 
Chlamydia infection, including environmental and epidemiological factors, co-infections 
and host’s genetic background, including HLA haplotypes and polymorphisms in 
inflammatory response genes. Chlamydia infections with increased or decreased risk of 
sequelae have been associated to genetic polymorphisms of hosts by several reports 
(reviewed in Puolakkainen 2009).  
 
2.1.9. Diagnostics 
 
Serology is commonly used to diagnose acute C. pneumoniae infections. According to the 
current recommendations from 2001 for C. pneumoniae serology, 
microimmunoﬂuorescence test (MIF) (Wang and Grayston, 1970) is considered the only 
acceptable approach (Dowell et al., 2001). This approach uses purified EB as an antigen. 
The method is species-speciﬁc and it is capable of measuring IgA, IgG and IgM 
antibodies. Separation between antibody classes is important in order to distinguish recent 
from past infection as well as primary from reinfection (Kuo et al. 1995). Interpretation of 
the results is not straightforward and requires an experienced microscopist. According to 
current recommendations, acute infection is deﬁned by a 4-fold rise in IgG or an IgM titer 
of ≥16 and the use of a single elevated IgG titer as diagnostic is discouraged. Past 
exposure is indicated by an IgG titer of ≥16 (Dowell et al., 2001).  In a primary infection, 
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the IgG antibody response may not appear until 6 to 8 weeks after the onset of illness, 
whereas the IgM antibody has been estimated to appear in three weeks after the onset 
(Kuo et al., 1995). The IgM response is low or absent in reinfection, and the IgG antibody 
rise can be measured earlier, within one to two weeks (Boman and Hammerschlag, 2002).  
 
Enzyme immununoassays (EIA) have potential for standardized performance, automation, 
and objective end points. EIA is also able to distinguish between IgA, IgG, and IgM 
antibody classes. In EIA, recombinant LPS antigen, LPS-extracted EB or synthetic 
peptides have been used as antigens. However, there have been problems with the 
sensitivity and specificity of the current EIA tests and cross-reactions between the 
chlamydial species have been observed (Boman and Hammerschlag, 2002, Hermann et 
al., 2002, Hoymans et al., 2003, Paldanius et al., 2006).  
 
Also a complement fixation test (CF) is used to study C. pneumoniae antibody levels. It 
measures antibody response against chlamydial LPS and therefore is unable to distinguish 
between Chlamydia species (Kuo et al., 1995). The advantage of the CF test is that 
chlamydial CF antibodies are produced rapidly and may be detected earlier than MIF IgM 
antibodies. On the other hand, the CF test is not suitable for detecting reinfections, where 
CF antibodies are often at low levels or absent (Kuo et al., 1995).  
 
Isolation of C. pneumoniae in cell culture is considered the only reliable method to 
confirm the viability of the organism in specimen (Dowell et al., 2001). However, it is not 
able to detect a viable RB form of Chlamydia. Detection of chlamydial RNA also suggests 
viable Chlamydia in a specimen, but RNA detection methods are not routinely used in C. 
pneumoniae diagnostics (Beagley et al., 2009). The propagation and isolation of C. 
pneumoniae in cell cultures is an important tool in research laboratories, but it is 
technically difficult and laborious, and therefore rarely used in routine diagnostics. 
 
PCR has established itself as a sensitive and specific technique that has become important 
to all areas of microbiology. However, it is essential that such parameters as sensitivity 
and speciﬁcity, reproducibility, and optimal sample types are determined before PCR 
becomes part of the routine diagnostic workflow. Also, the PCR protocols used in the 
research laboratory need to be thoroughly validated in order to produce reliable research 
results.  In general, C. pneumoniae PCR can be considered at least as sensitive as culture 
(Murdoch, 2003). C. pneumoniae DNA can be detected in both upper and lower 
respiratory tract samples, but it is unclear which respiratory sample is optimal for PCR 
testing (Murdoch, 2003). Some investigators have found more PCR positive results for 
upper than for lower respiratory tract samples, but C. pneumoniae DNA positive upper 
respiratory samples may represent an asymptomatic infection (Verkooyen et al., 1998, 
30 
 
Murdoch, 2003). Vascular tissue specimens and PBMC have been subjected to PCR to 
investigate the association between C. pneumoniae and cardiovascular disease. However, 
the rate of positive findings varies considerably between different studies (Boman and 
Hammerschlag, 2002) and agreement is poor between different laboratories even when the 
same samples are analyzed (Apfalter et al., 2001) highlighting the need for careful 
validation and standardization of the used techniques. Currently, real time PCR techniques 
are commonly used both for diagnostic and research purposes.  The method has several 
advantages: the specificity (if a probe is included in the PCR reaction) and sensitivity are 
good and comparable to conventional PCR combined to hybridization. The method is 
rapid and no post PCR manipulations are needed, thus preventing contamination problems 
(Espy et al., 2006). Multiplex PCR-methods in combination with microarray technology 
are becoming routine in microbial diagnostics (Tissari et al., 2010) allowing simultaneous 
identification of several microbial targets in one specimen. This technology can also be 
used to genotype microbes and recently a genotyping assay for C. trachomatis has been 
published (Ruettger et al., 2011). In addition to PCR, the presence of C. pneumoniae 
organism, nucleic acid or antigen can been detected from various samples by, electron 
microscopy, immunohistochemistry or in situ hybridization (Kuo et al., 1995).  
 
At present there is no widely accepted serologic marker for persistent or chronic C. 
pneumoniae infection. High IgA antibody titers have been proposed as a marker of chronic 
C. pneumoniae infection, since the half-life of serum IgA is less than 7 days, compared to 
several weeks for IgG (Boman and Hammerschlag, 2002). Elevated serum C. pneumoniae 
IgA and IgG antibodies and C-reactive protein has been associated with acute coronary 
syndromes and asthma (Huittinen et al., 2003, Miya et al., 2004, Sävykoski et al., 2004). 
Recently Tiirola et al. developed an assay for the measurement of chlamydial 
lipopolysaccharide in serum. The chlamydial LPS was observed more frequently and in 
higher amounts in patients with acute coronary syndrome and they concluded that the 
method has potential, at least on an epidemiological level, for detecting chronic C. 
pneumoniae infection (Tiirola et al., 2006). 
 
2.1.10 Treatment 
 
Macrolides (erythromycin, roxithromycin, clarithromycin, and azithromycin), 
fluoroquinolones (levofloxasin, gatifloxacin, moxifloxasin, gemifloxasin and 
garenoxacin), tetracyclines, and the new ketolide antibiotic telithromycin exhibit good in 
vitro activity against C. pneumoniae (Hammerschlag et al., 2001, Blasi, 2004). Current 
treatment recommendations for C. pneumoniae pneumonia include macrolide, 
telithromycin or tetracycline as first-line therapy and fluoroquinolone for alternative 
antimicrobial (Mandell et al., 2007, Honkanen et al., 2008) and prolonged therapy of 10-
14 days has been recommended (Kuo et al., 1995, Hammerschlag et al., 2001, Blasi, 
2004).  However, the treatment of chronic C. pneumoniae infections may be problematic. 
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The normal dosage and duration of antibiotic monotherapy for C. pneumoniae infection 
may not be sufﬁcient to eradicate a persistent infection, whereas suboptimal antibiotic 
treatment may trigger persistent C. pneumoniae infection (Matsumoto and Manire, 1970, 
Gieffers et al., 2001, Kutlin et al., 2002). In the tissue the delivery of the drugs to the 
inclusion may be inefficient resulting in suboptimal concentrations inside the inclusion. 
Thus, new strategies for managing C. pneumoniae infection are needed and several new 
promising natural and synthetic compounds with antichlamydial activity have been 
identified (Donati et al., 2005, Erkkilä et al., 2005, Törmäkangas et al., 2005b, Alvesalo et 
al., 2006a, 2006b, Wolf et al., 2006, Muschiol et al., 2009). Polyphenolic compounds 
have anti-inﬂammatory and anti-microbial potential and plant polyphenolic compounds 
may play a role in protection against cardiovascular diseases through their antioxidative 
properties (Reed, 2002, Aviram et al., 2002, Vuorela et al., 2004). Several flavonoids 
possess antichlamydial activity and luteolin is among the compounds with perhaps the 
greatest potential in restricting chlamydial gowth and reducing inflammatory responses 
(Törmäkangas et al., 2005b, Alvesalo et al., 2006b). Cathelicidins are a family of 
antimicrobial peptides acting as effector molecules of innate immunity and exerting potent 
antimicrobial activities. In a study by Donati et al. cathelicidin peptide SMAP-29 proved 
to be most active against chlamydial infection (Donati et al., 2005). Statins are efficient 
drugs that are used to reduce serum LDL cholesterol levels. In addition, statins have been 
shown to reduce C. pneumoniae growth both in cell cultures and experimental infections 
in mice (Kothe et al. 2000, Erkkilä et al., 2005). The availability of synthetic small 
molecule inhibitors of the Yersinia type III secretion system (INPs) is providing new tools 
to modulate T3SS activity, and INPs have been reported to disrupt progression of the 
chlamydial developmental cycle and to have a strong inhibitory effect on chlamydial 
growth (Wolf et al., 2006, Muschiol et al., 2009). Also, vitamin D has recently been 
reported to have antichlamydial activity both in cell cultures and in experimental 
infections through induction of antimicrobial peptides (He et al., 2010). 
 
3. PERSISTENT CHLAMYDIA PNEUMONIAE INFECTION 
 
Clamydial persistence has been defined as a viable but noncultivable growth stage 
resulting in a long-term relationship with the infected host cell (Beatty et el., 1994a). The 
persistence is best characterized in vitro (Figure 3.) but evidence for its existence in vivo 
has also been obtained from experimental animal models and from natural infections in 
humans. As already discussed earlier in chapter 2.1.7. (Cell tropism), morphologically 
aberrant chlamydial forms have been observed in diseased tissues in association with 
human chronic disease. Persistent pulmonary C. pneumoniae infections with recurrences 
despite of antibiotic treatment have been described.  (Falck et al., 1994, Falck et al., 1996, 
Miyashita et al., 2002). Additional evidence supporting the occurrence of persistent C. 
pneumoniae infection in vivo comes from experimental infection models where culture-
negative C. pneumoniae infection have been reactivated with corticosteroid treatment 
(Malinverni et al., 1995, Laitinen et al., 1996).  
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Figure 3. Schematic presentation of establishment and activation of a persistent C. pneumoniae infection in 
an eukaryotic cell.
 
 
 
3.1 In vitro models of persistent Chlamydia infection 
It would be ideal if the mechanisms of persistent chlamydia infection could be studied in 
vivo in humans. However, there are several limitations in practice. To study the basic 
mechanisms of persistence e.g. by microarray analysis, a large number of C. pneumoniae
infected cells are needed, which is difficult and in some cases even impossible to obtain 
from one individual. Furthermore, the biological variance between individuals would 
interfere with interpretation of the results. Animal models e.g. the mouse model is a good 
option, but the found mechanisms might not reflect the mechanisms in humans, therefore 
also studies in cell culture systems are needed. In vitro infection models provide a
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practical approach, although a simplified model, to study mechanisms of persistent C. 
pneumoniae infection with an unlimited source of human cells. 
 
Ultrastructurally characterized penicillin-induced in vitro persistence of C. psittaci 
infection has been described already in 1970 by Matsumoto and Manire. Upon exposure to 
penicillin, the chlamydial RB exhibited aberrant enlarged morphology typical for 
persistent Chlamydia infection and were unable to divide. Removal of penicillin from the 
culture media recovered the aberrant RB back to normal ones (Matsumoto and Manire, 
1970). The effect of penicillin exposure is similar for C. trachomatis and C. pneumoniae 
(Skilton et al., 2009, Peters et al., 2005). Also, exposure to suboptimal levels of antibiotics 
used in treatment such as tetracycline, erythromycin, rifampin, and ciprofloxacin have 
been shown to induce in vitro persistent infections of C. trachomatis and C. pneumoniae 
(Kramer and Gordon, 1971, Clark et al., 1982, Hammerschlag and Vuletin, 1985, Gieffers 
et al., 2004a). Thus, suboptimal antibiotic treatment may cause chlamydial persistence 
also in vivo.   
 
The importance of nutrients such as amino acids, glucose and vitamins to active growth of 
C. psittaci was shown already 50 years ago (Morgan, 1956, Bader and Morgan, 1958, 
1961). In these initial in vitro studies, Chlamydia was shown to be able to invade the host 
cell in a nutrient deficient medium and remain noninfectious but viable in the cells (Bader 
and Morgan, 1958, Bader and Morgan, 1961).  More recently, Coles et al. showed 
decreased infectivity and production of aberrant C. psittaci and C. trachomatis 
morphology when all 13 amino acids were depleted progressively. Upon restoration of 
amino acids in the growth media the productive infection was resumed (Coles et al., 
1993). Amino acid levels present in plasma have been shown to produce aberrant 
chlamydial forms with reduced infectivity, suggesting that nutrient levels in vivo could 
promote abnormal chlamydial development (Harper et al., 2000).  
 
Iron depletion by addition of the chelating compound deferoxamine mesylate (DAM) has 
also been shown to restrict the growth of C. pneumoniae, C. trachomatis and C. psittaci. 
Upon iron depletion, the RB are enlarged and pleomorphic, exhibiting a wavy appearance 
of the outer membrane (Raulston, 1997, Al-Younes et al., 2001, Goellner et al., 2006). A 
number of chlamydial enzymes require iron for their activities and therefore the growth 
restriction may be directely due to the lack of iron (Al-Younes et al., 2001). The growth 
restriction can be reversed by adding iron loaded transferrin to the growth media (Al-
Younes et al., 2001, Kutlin et al, 2001, Goellner et al., 2006). One of the host cell’s 
defense mechanisms against bacterial infections is the induction of iron-chelating agents, 
which may lead to iron deficiency in vivo.  
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Exposure of host cells to moderate levels of IFN-γ restricts chlamydial growth and leads to 
the development of atypical aberrant RB. The RB are typically enlarged due to the 
inhibition of cell division and the maturation of RB to infectious EB is minimal. Like in 
other described models, the alterations in the developmental cycle are reversible and upon 
removal of IFN-γ aberrant RB restart division and maturate into infectious EB (Beatty et 
al., 1994a). Well characterized models of IFN-γ induced persistent infection have been 
described to C. psittaci, C. trachomatis and C. pneumoniae (Byrne et al., 1986, Beatty et 
al., 1993, Pantoja et al., 2001).  The major mechanism of IFN-γ action on chlamydia is 
based on the induction of indoleamine 2,3-dioxygenase (IDO), a host cell enzyme 
involved in tryptophan catabolism. In other words, the IFN-γ model of persistent 
Chlamydia infection is also based on amino acid depletion and addition of exogenous 
tryptophan, and in the case of genital C. trachomatis serovars also indole reverses IFN-γ 
induced growth restriction (Beatty et al., 1994c, Caldwell et al., 2003). Genital serovars of 
C. trachomatis possess functional tryptophan synthase genes and are able to convert 
indole into tryptophan. Other microbes in vaginal flora may provide the indole into the 
environment allowing the escape of C. trachomatis from the growth inhibitory 
mechanisms of IFN-γ. C. pneumoniae lacks the genes for tryptophan synthase and ocular 
serovars C. trachomatis have frame-shift mutation in the trpA gene resulting in a 
nonfunctional enzyme (Caldwell et al., 2003). In addition to induction of IDO, IFN-γ is 
known to induce tryptophanyl-tRNA synthetase in fibroblasts and epithelial cells (Rubin 
et al., 1991, Flohr et al., 1992), which possibly further depletes the tryptophan pool 
available for Chlamydia.  
 
The IFN-γ model for persistent Chlamydia infection is perhaps the most widely used and 
has particular relevance in vivo since Chlamydia infection is known to elicit the IFN-γ 
response (Numazaki and Chiba, 1996, Penttilä et al., 1998). High levels of IFN-γ 
successfully eradicate Chlamydia, however low levels of IFN-γ may be a result of a too 
weak Th1 type immune response or a dominant Th2 type immune response favoring the 
establishment of a persistent infection. The situation in vivo is more complex than that in 
the in vitro model. The level of IDO expression is affected by numerous factors including 
the host cell type and the anatomical location (Sakash et al., 2002, Sedlmayr et al., 2002). 
A recent report implicates that hypoxia abrogates anti-chlamydial effects of IFN-γ, 
reduces IDO expression, and rescues genital C. trachomatis from IFN-γ induced 
persistence (Roth et al., 2010), while another recent study reports that IFN-γ secretion by 
CD4+ T-cells is significantly enhanced under hypoxic conditions (Roman et al., 2010). 
Also, synergy in restricting chlamydial growth with other cytokines, especially with tumor 
necrosis factor alpha (TNF-α) has been described in vitro (Summersgill et al., 1995, 
Cheshire and Baldwin, 1997, Igietseme et al., 1998, Matsushima et al., 1999) and is likely 
relevant also in vivo. Recently Tietzel et al. reported that human guanylate binding 
proteins (hGBP) 1 and 2 potentiate the anti-chlamydial effect of IFN-γ (Tietzel et al., 
2009) and in addition to IFN-γ, hGBP1 and 2 are induced by TNF-α and IL1 (Tripal et al., 
2007). Alone or together with other cytokines IFN-γ may also contribute to other 
35 
 
inhibitory systems restricting chlamydial growth such as nitric oxide induction and iron 
deprivation (Byrd and Horwitz, 1993, Igietseme et al., 1998).  
 
Continuous chlamydial cultures were initially described for C. psittaci (Moulder et al., 
1980) and later also for C. trachomatis and C. pneumoniae (Lee, 1981, Kutlin et al., 
2001). A continuous Chlamydia infection can be established without external induction 
and resembles the other persistent in vitro models with the appearance of spontaneous 
abnormal chlamydial inclusions. These cultures alter between periods of chlamydial 
multiplication, induced host cell destruction, and periods of cell proliferation, and these 
cells can be cultured indefinitely (Moulder et al., 1980, Lee, 1981, Kutlin et al., 2001).   
 
C. pneumoniae and C. trachomatis infection of monocytes resembles a persistent infection 
with minimal bacterial cell division, and with a low level of infectious progeny. Aberrant 
RB morphology is detected and viability of Chlamydia can be shown by detection of 
bacterial mRNA (Koehler et al., 1997, Airenne et al., 1999). The mechanism of 
chlamydial growth restriction in mononuclear cells remains unknown, but IDO is not 
likely to play a role, since Chlamydia remains nonproductive in monocytic cultures after 
the addition of tryptophan (Koehler et al., 1997, Airenne et al., 1999).  
 
Tobacco smoke has been reported to induce C. pneumoniae infections with characteristics 
of persistent infections in epithelial and endothelial cell lines (Wiedeman et al., 2004, 
2005). Infection of epithelial cells with C. psittaci and bacteriophage φCPG1 have been 
shown to switch the bacteria into an altered developmental cycle resembling persistent 
infection (Hsia et al., 2000) and persistent chlamydia forms have been observed in 
coinfections of C. trachomatis with HSV-2 and Chlamydia abortus or Chlamydia 
pecorum with porcine epidemic diarrhea virus (Deka et al., 2006, Vanover et al., 2008, 
Borel et al., 2010). Also, C. pneumoniae is susceptible to phage infection, C. pneumoniae 
AR-39 harbors phage sequenses in its genome (Read et al., 2000, Karunakaran et al., 
2002, Rupp et al., 2007) and coinfections of C. pneumoniae with an other respiratory 
pathogens are common (Kauppinen et al., 1995, 1996, Heiskanen-Kosma et al., 1999, 
Monno et al., 2002). Whether superinfection with a bacteriophage or other microbial 
pathogen can induce persistent appearance of C. pneumoniae, is still unknown.  
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4. MOLECULAR STUDIES OF CHLAMYDIA PNEUMONIAE – 
HOST INTERACTIONS 
 
4.1. Transcriptomics 
 
There are several options to study C. pneumoniae – host cell interactions on the level of 
gene transcription. Conventionally Northern blot analysis has been used to study 
differential transcription of host cells and pathogens, and later reverse transcriptase PCR 
(RT-PCR) became available. Presently, “real-time” formats of this technique are widely 
used to study the expression of focused gene sets. More recently, microarray techniques 
have become available allowing for the simultaneous determination of the RNA levels of 
thousands of specific mRNA species.  
 
There are varieties of technical solutions for performing microarray analysis, but in 
essence they are all miniaturized hybridization assays, where the array contains 
immobilized nucleic acid sequences and detection is based on the hybridization of labeled 
complementary sequences. In gene expression profiling, mRNA is isolated from the 
samples of interest and usually reverse transcribed into cDNA or amplified into cRNA and 
labeled with a fluorochrome. The labeled cDNA is hybridized to the array containing 
nucleic acid sequences, representing a specific gene, spotted to the array in an orderly 
pattern. After the hybridization step, the microarrays are scanned and fluorescence 
intensities are measured.  In transcription studies, the two-color hybridization is often used 
where cDNA molecules from two different conditions are compared to each other and are 
labeled with different colors. By measuring the different fluorescent signals associated to 
each spot on the array, the relative abundance of a specific transcript of each studied 
condition can be determined (Leroy and Raoult, 2010).  
 
Microarray techniques have been used to study transcriptional host cell responses to C. 
pneumoniae infection (Coombes and Mahony 2001, Hess et al., 2003, Virok et al., 2003,  
Shi and Tokunaga, 2004, Eickhoff et al., 2007, Wang et al., 2010) and to target putative 
drug molecules (Alvesalo et al., 2008). In some studies, the importance of up-regulated 
host cell molecules in C. pneumoniae infection has been further characterized by knocking 
down the gene transcript with small inhibitory RNA molecule (Alvesalo et al., 2008, 
Wang et al., 2010). Most information of host cell responses to C. pneumoniae infection 
comes from in vitro models of active infection. Also, the genomic transcriptional activity 
of C. pneumoniae during the developmental cycle has been characterized by microarrays 
(Ouellette et al., 2006, Mäurer et al., 2007).  
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Very little is known about host cell response to persistent C. pneumoniae infection. 
Chlamydia infection of monocytes is considered to represent persistent Chlamydia 
infection and Virok et al. have studied host cell gene expression by microarray in 
monocytic cell line infected with C. pneumoniae.  They found that several molecules 
linked to the development of atherosclerosis and other chronic inflammatory diseases were 
up-regulated in monocytes in response to C. pneumoniae infection (Virok et al., 2003). 
Peters et al. studied seven selected key host molecules of cellular signaling pathways 
known to be up-regulated in C. pneumoniae infection. The expression of the selected host 
molecules was studied in monocytes and in three different in vitro models of persistent C. 
pneumoniae infection in epithelial cells by RT-PCR (CTGF, IL-8, LIF, EGR-1 and ETV4) 
or ELISA (IL-6 and IL-11). It was demonstrated that depending on the cell type, different 
signaling cascades are turned on in persistence and depending on the mode that persistent 
infection is induced in epithelial cells, either permanent activation or silencing of the 
studied host gene is observed (Peters et al., 2005). A later study by the same group 
identified 17 human host cell genes related to apoptosis, the cell cycle, or metabolism as 
both up- or down-regulated in IFN-γ induced persistent infection of epithelial cells by 
microarray analysis and real-time PCR (Eickhoff et al., 2007).  
 
Transcription of chlamydial genes in different models of persistent C. pneumoniae 
infection in epithelial cells has been conducted both by microarray and RT-PCR studies 
(Byrne et al., 2001, Mathews et al., 2001, Hogan et al., 2003, Mäurer et al., 2007, 
Ouellette et al., 2006,  Polkinghorne et al., 2006, Slepenkin et al., 2003, Timms et al., 
2009).  By microarray analysis Ouellette et al. noticed global transcriptional up-regulation 
of C. pneumoniae gene transcription in IFN-γ induced persistent infection of epithelial 
cells without increased translation (Ouellette et al., 2006). In contrast, Mäurer et al., 
observed global down-regulation or arrest of the transcription during mid phase in the iron 
limited persistent C. pneumoniae infection model. They found σ28, which regulates some 
of the late genes, to be specifically down regulated (Mäurer et al., 2007). The low level of 
infection attained in mononuclear cells has hindered the use of genome-wide approaches 
to analyze bacterial transcription in mononuclear cells and thus there is only limited 
knowledge of the transcription of C. pneumoniae genes in monocyte/macrophages 
(Airenne et al., 1999, Gieffers et al., 2001, Haranaga et al., 2003, Klos et al., 2009). 
Before the entire chlamydial genome was sequenced, molecular studies focused on small 
group of genes thought to be key antigens in persistence. Early studies with C. 
trachomatis showed decreased expression of MOMP and Omp2 and increased expression 
of Hsp60 (Beatty et al., 1993, Beatty et al., 1994b). Since then, these molecules have been 
extensively studied in models for persistent C. pneumoniae infection without uniform 
outcome (Airenne et al., 1999, Gieffers et al., 2001, Mathews et al., 2001, Mäurer et al., 
2007, Ouellette et al., 2006, Polkinghorne et al., 2006, Haranaga et al., 2003, Slepenkin et 
al., 2003) and therefore cannot be considered as universal markers of persistent chlamydia 
infection. In 2001 Byrne et al. showed in the IFN-γ induced persistent infection model 
attenuated levels of expression of genes involved in cell division while genes involved in 
DNA replication were unaffected agreeing with the observation that in persistent C. 
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pneumoniae infection enlarged RB are formed (Byrne et al., 2001). Other molecules 
recently reported to be differentially expressed during persistent Chlamydia infection 
include the stress response related gene htrA, the early transcribed gene euo, genes 
encoding phospholipase D-like enzymes, ribosomal proteins, histone-like proteins, signal 
transduction genes, proteases, peptide transporters, and T3S associated genes among 
others (Belland et al., 2003b, Hogan et al., 2004, Polkinghorne et al., 2006, Ouellette et 
al., 2006, Mäurer et al., 2007, Timms et al., 2009).  
 
4.2. Proteomics  
 
Proteomics refers to a procedure that characterizes large sets of proteins. The ideal 
proteome study would provide quantitative information and identification of all proteins in 
a biological sample analyzed. Such a technique does not exist yet but there has been 
promising development in the methodology (Malmström et al., 2007, Sleno and Emili, 
2008). Proteomic approaches can be used e.g. for proteome proﬁling, comparative 
expression analysis, identiﬁcation of posttranslational modiﬁcations, and to study protein–
protein interactions (interactomics). The proteome approaches lack sensitivity in 
comparison to transcriptome methodologies, but they have some advantages. The stability 
of an RNA transcript affects its translation and protein production from a transcript may 
be post-transcriptionally regulated, and hence information obtained at the transcriptional 
level does not always reflect the situation at the protein level. An advantage of a proteomic 
approach is also its ability to detect proteins in their post-translationally modified and 
processed form. In the most used proteome approach proteins are separated in two-
dimensional polyacrylamide gel electrophoresis and separated spots are identified by mass 
spectrometry methodologies. Protein arrays are an emerging technology in proteomics and 
allow the detection and the comparison of large number of different proteins 
simultaneously (Sleno and Emili, 2008). The protein array technology is still in its 
infancy, but it has great potential.   
 
Proteome analyses have been used to construct a proteome map of C. pneumoniae 
(http://www.gram.au.dk, http://www.mpiib-berlin.mpg.de/2D-PAGE), to identify secreted 
C. pneumoniae proteins, to characterize constituents of chlamydial OMC, and to identify 
proteins differentially expressed in persistent infection models (Vandahl et al., 2004). The 
first proteomic analysis of persistent C. pneumoniae infection was published by Molestina 
et al. in 2002. They observed up-regulation of MOMP, Hsp60, and seven other proteins 
with functions in DNA replication, transcription, translation, glycolysis, and type III 
secretion at 24 hours after infection in IFN-γ induced persistent infection of HEp-2 
epithelial cell line (Molestina et al., 2002). In a study by Wehrl et al. 11 proteins were 
identified as up-regulated and eight as down-regulated in an iron limitation model of 
persistent C. pneumoniae infection in HEp-2 cells (Wehrl et al., 2004b). In an extensive 
study by Mukhopadhyay et al., protein expression profiles of IFN-γ and iron limitation 
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models of persistent C. pneumoniae infection in HEp-2 cells were compared to those of 
heat shock stress response. They showed that although persistent C. pneumoniae infection 
contains a stress component it is clearly more than just a stress response. All three studied 
conditions induced up-regulation of stress response proteins DnaK, HtrA, ClpP_1, and 
ClpP_2, and down-regulation of Gcp_1 involved in folding, assembly, and modification of 
proteins and down-regulation of Ndk involved in amino acid biosynthesis. In IFN-γ 
induced persistent infection many proteins involved in the biosynthesis of amino acids and 
nucleotides were specifically up-regulated and in the iron limitation model proteins 
functioning in biosynthesis of cofactors, cellular processes, energy metabolism, 
transcription, and translation were specifically up-regulated (Mukhopadhyay et al., 2006).  
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5. AIMS OF THE STUDY 
 
The overall aim of this work was to study Chlamydia-host cell interactions in persistent 
infection models and to identify possible host cell or bacterial genes important for 
pathogenesis of persistent infection or as putative markers of persistent C. pneumoniae 
infection. 
 
The specific aims of this study were: 
 
i. to set up active and persistent C. pneumoniae infection models in epithelial and 
monocyte/macrophage cell lines 
ii. to establish detection methods for C. pneumoniae genomes and transcripts in 
the infection models  
iii. to study host cell responses to persistent C. pneumoniae infection and compare 
the obtained results to those from an active infection  
iv. to study transcription of selected C. pneumoniae genes during the infection of 
monocytes  
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6. MATERIALS AND METHODS 
 
Bacterial strains, cell lines and plasmids used in this study are listed in Table 4. The 
methods used in this study are described in detail in the indicated articles and are 
summarized in Table 5.  
Table 4. Bacterial strains, cell lines and plasmids used in this study 
Strain or 
 cell line Description Article Source/Reference 
Bacterial 
strains:    
K6 C. pneumoniae isolate Kajaani 6 I-III 
Prof.Saikku/Ekman et al., 
1993  
JM109 E. coli I, III  
Cell lines:    
HL Human line, an epithelial cell line I-III Kuo and Grayston, 1990 
Mono Mac 6 Human monocytic cell line I,III 
DSMZ 124/ Ziegler-
Heitbrock et al., 1988 
Plasmids:    
pGEM-T Procaryotic cloning vector I Promega 
pSTBlue-1  Procaryotic cloning vector III Novagen 
 
Table 5. Methods used in this study  
Method Described and used in 
C. pneumoniae culture conditions:  
Active infection in HL cells I-III 
Persistent infection in HL-cells I-III 
Infection in monocytes I,III 
Molecular biology methods:  
Molecular cloning I,III 
In vitro transcription III 
PCR I-III 
RT-PCR I-III 
Microarray II 
Microscopy:  
Electron microscopy I 
Immunofluorescence microscopy I-III 
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7. RESULTS AND DISCUSSION 
 
7.1. The quantitative PCR method (qPCR) for C. pneumoniae DNA (I) 
and transcripts (III) 
 
To measure C. pneumoniae genomes in cell cultures, a quantitative real-time PCR (qPCR) 
method, using dual-labeled hydrolysis probes targeting ompA gene, was set up and 
optimized. After optimization and validation, it was used in all studies (I-III) to measure 
C. pneumoniae genomes during active and persistent infection. The qPCR assay could 
reproducibly detect 10 C. pneumoniae genome equivalents (GE) per reaction showing 
good analytical sensitivity comparable to that of previously reported quantitative PCR 
assays for C. pneumoniae (Berger et al., 2000, Huang et al., 2001, Mygind et al., 2001). 
The efficiency of amplification was 95-100%.  The intratest coefficient of variation (CV) 
was 5.0% - 12.2% depending on the used C. pneumoniae amount and the intertest CV was 
at the highest 21%, when 100 genomes/reaction were used, indicating good reproducibility 
for the method. When the results of the qPCR were compared to those of quantitative 
culture of C. pneumoniae with purified EB preparations and infected murine tissues as 
starting material, there was in general a 100-fold difference in the amount of C. 
pneumoniae detected by these methods. This suggests that the amplification method is 
more sensitive than the culture method in detection of C. pneumoniae, and that the 
purified chlamydial preparations as well as the tissue specimens from infected animals 
contain a mixture of infectious and non-infectious chlamydial particles (I). 
 
To analyze transcription of 11 C. pneumoniae genes in Mono Mac 6 cells during infection 
real time RT-PCR methods with dual-labeled hydrolysis probes were set up for each gene. 
Our primary interest was to study the genes for secreted proteins (incA, cpaf, cpn0572, 
cpn0809, and lcrE) and the genes (ompA, omp2, ftsK, euo, htrA and hsp60) that were 
previously found differentially expressed in persistent infection models in epithelial cell 
lines. The analytical sensitivity of the set up assays were 50-100 RNA copies/reaction as 
determined by dilution series of in vitro transcripts of the corresponding gene. The 
sensitivities of the assays are comparable to those reported for other RT-qPCR assays 
(Escaffre et al., 2010, Kitajima et al., 2010). Both the amount of C. pneumoniae DNA and 
the number of 16S rRNA transcripts have been used to normalize C. pneumoniae gene 
transcription data (Polkinghorne et al., 2006, Ouellette et al., 2006, Timms et al., 2009). 
We normalized our data for both the C. pneumoniae DNA measured as genome 
equivalents (GE) and the 16S rRNA transcripts. There were no significant differences in 
the transcription data between the two normalization methods (III). However, deviations 
between the replicate samples were slightly lower (CV% 41 vs. CV% 49) when the 16S 
rRNA was used for normalization (III) and the DNA from nonviable chlamydial particles 
in Mono Mac 6 cells is known to degrade slowly (I). Hence, the C. pneumoniae gene 
transcription data normalized to 16S rRNA transcripts is presented here, although 
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normalization based on the DNA content was preferred for normalization of chlamydial 
gene expression in epithelial cells under different growth conditions (Ouellette et al., 
2006). As controls, IFN-γ exposed (representing persistent infection) and unexposed 
(representing active infection) HL cells were infected with C. pneumoniae. Our aim was to 
ascertain that the results based on our infection model in epithelial cells, including the use 
of Kajaani-6 isolate of C. pneumoniae, and the developed methodology for measuring C. 
pneumoniae transcripts were in agreement with those obtained in earlier studies on C. 
pneumoniae grown in epithelial cells. The transcription of the panel of 11 genes was 
studied with RT-PCR analysis. The panel included three stage-specific genes: 1. Early-
cycle gene euo, 2. Mid-cycle gene ompA, and 3. Late-cycle gene omp2 (omcB) (Ouellette 
et al. 2006, Mäurer et al. 2007). Transcription profiles of the three stage-specific genes in 
HL cells were as reported earlier and the expression profiles of incA, hsp60, cpn0809, 
ftsK, and htrA genes during infection of HL cells were similar to those described earlier 
for epithelial cell cultures (III, Mathews et al., 2001, Polkinghorne et al., 2006, Mäurer et 
al., 2007, Timms et al., 2009). 
 
7.2. Model for active C. pneumoniae infection in epithelial cell line (I) 
 
C. pneumoniae culture is most successful in HL (Cles and Stamm, 1990, Kuo and 
Grayston 1990) and Hep-2 (Roblin et al., 1992) epithelial cells. Here growth of the 
C.pneumoniae K6 isolate was characterized by qPCR, an infectivity assay, and 
microscopy in HL cells. The cell cultures were monitored for 8 days (192 hours) after 
inoculation. In the cells collected early at the developmental cycle, immediately after the 
inoculation or 24 h later, very few infective EB could be detected (Figure 1./I) suggesting 
that nearly all EB inside the cells had transformed into RB.  The RB differentiation to EB 
occurred most rapidly between 36 and 48 hours after inoculation, but the highest amount 
of EB was cultured from the cells at 72 hours after inoculation (hai) (Figure 1, I).  The 
number of C. pneumoniae genomes decreased rapidly between 0 and 12 hai and a similar 
decrease was observed when cells were inoculated with heat and UV inactivated C. 
pneumoniae.  At 12 hours after inoculation only ~10% of the GE detected at 0 h post 
inoculation still existed and at 72 hours after inoculation only a minor fraction (3-6%) of 
the initial GE remained in the cells inoculated with heat or UV inactivated C. pneumoniae. 
The observed decrease in the GE number early in the cycle may reflect the presence of 
nonviable EB in the used C. pneumoniae stock or EB being unable to initiate productive 
infection for other reasons. Accumulation of the C. pneumoniae genomes started at 12-24 
hours after infection (Figure 1./I) and the replication of the genomes still continued after 
48 hours after infection although most RB had, based on the growth curve (Figure 1./I), 
already matured into EB, reflecting the asynchronous nature of the later stages of C. 
pneumoniae developmental cycle (Wolf et al., 2000). Why relatively synchronous 
developmental cycle becomes asynchronous at later stages is not known, but it has been 
speculated that the dissociation of dividing RB from the inclusion membrane in 
consequence of the lack of space could trigger RB to EB differentiation, and thus 
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contribute to the asynchronous nature of the late developmental cycle (Bavoil et al., 2000, 
Hoare et al., 2008).  
 
By quantitating C. pneumoniae genomes by qPCR, we predicted the doubling time of C. 
pneumoniae genome in HL cells using the method of Mathews et al. with modifications 
(Mathews et al., 1999). Between 12 and 24 h after inoculation, there was already an 
increase in the number of C. pneumoniae genomes. Thus, 12 h after infection was 
assigned as the replication starting point for this model, and then theoretical DNA 
replication profiles assuming a doubling time of 6, 7 and 9 hours were calculated using 12 
hai as a starting point. These replication profiles were then compared to the observed 
genome replication rates. Based on the accumulation of genome sequences during the 
exponential phase of genome replication between 12 and 48 h after inoculation, the curve 
of active C. pneumoniae K6 culture lies between 6 and 7 hours doubling time (Figure 4./ 
I). The observed doubling time of 6-7 hours is longer than the doubling time observed for 
faster growing C. trachomatis L2 (Mathews et al., 1999). In a recent study Mitchell et al. 
found similar doubling time (5.9-8.7 h) for the C. pneumoniae human isolate AR39 grown 
in Hep-2 cells. However, a much faster doubling time (3.4-4.9 h) was observed for the C. 
pneumoniae koala isolate LPCoLN in Hep-2 cells (Mitchell et al., 2009). Whether this 
reflects differences between human and koala isolates or different pathotypes, is unknown. 
 
The growth curve of C. pneumoniae K6 in HL cells was found similar to that reported 
earlier for C. pneumoniae AR-39 in HL cells and in HeLa 229 cells (Kuo and Grayston 
1990, Wolf et al., 2000). In agreement with previous study (Kuo and Grayston, 1990), a 
second cycle of C. pneumoniae growth in HL cells was detected at 72-96 h after 
inoculation, as the number of EB recovered and genomes detected decreased, but 
increased again at 92 to 168 h after infection (Figure 1./I). This ability to spread to new 
cells and initiate a new cycle of growth is critical for Chlamydia in order to survive and 
disseminate.  
 
7.3. Model for persistent C. pneumoniae infection in epithelial cells (I) 
 
Chlamydia is able to modulate the gene expression and apoptosis of host cells, which may 
assist Chlamydia to evade the hosts’ immune responses. This, in turn, may lead to 
extended survival of the organism inside epithelial cells and promote the development of 
persistent infection. To simulate persistent C. pneumoniae infection in vivo, we set up a 
persistent infection model, exposing the HL cell cultures to IFN-γ.  At that time little 
information was available on the kinetics of chlamydial DNA replication and genome load 
during persistence in host cells. We studied the effect of different concentrations of the 
cytokine to C. pneumoniae growth and chose the appropriate IFN-γ concentration to 
establish the persistent infection model. This model was characterized by measuring the 
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number of C. pneumoniae genomes by qPCR, maturation by infectivity assay and 
assessing the morphology of inclusions and the bacteria by immunoflurescence and 
electron microscope. Growth of C. pneumoniae was monitored in the cell cultures for 8 
days (192 hours) after inoculation. In agreement with previous studies, exposure of HL 
cells to IFN-γ dose-dependently inhibited differentiation (Mehta et al., 1998, Summersgill 
et al., 1995 ) and DNA-replication of C. pneumoniae, but the amount of cytokine required 
to reduce DNA-replication was higher than that needed to stop the production of C. 
pneumoniae able to infect new cells (Byrne et al., 2001) (Table 1./I). Altered inclusion 
morphology was observed at IFNγ concentrations of 15-25 U/ml: The inclusions were 
smaller in size and stained less intensely than the inclusions observed in untreated cells. At 
an IFN-γ concentration of 25 U/ml, the number of inclusion forming units produced per 
well decreased 20-fold (P<0,01) when compared to that of untreated cultures, whereas the 
number of C. pneumoniae genomes remained unaltered (P>0,05). At concentrations of 
>25 U/ml, IFN-γ abolished the production of infectious C. pneumoniae EB and reduced 
the number of GE in HL cells (Table 1./I). An IFN-γ concentration of 25 U/ml, which 
significantly reduces the production of infectious EB, but does not affect DNA replication, 
was chosen to induce persistent C. pneumoniae infection in HL cells in the following 
experiments. 
 
During IFN-γ induced persistent infection, the growth kinetics of C. pneumoniae in HL 
cells was similar to that of active growth during the first 72 h (Figure 1./I). There was also 
no significant difference in the doubling time of the C. pneumoniae genome during active 
infection and IFN-γ induced persistent infection (Figure 4./I). However, no second cycle 
of infection could be observed, and the number of infectious C. pneumoniae particles and 
GE remained rather stable after 72 h after inoculation (Figure 1./I). Also, with 
fluorescence microscopy small inclusions were seen to remain in the IFN-γ treated cells 
through the observation period of 8 days, whereas in untreated cells a remarkable 
reduction in the number of inclusions was observed at 110 h after inoculation. 
 
We estimated the level of C. pneumoniae persistence in cultured cells by calculating the 
ratio of infectious particles/ GE at different time points (Table 2./I). During active 
infection, the highest ratio (0.77) was achieved at 72 h after inoculation, when C. 
pneumoniae is considered to complete its development cycle in the epithelial cell culture 
(Kuo and Grayston, 1990). This value was used as a reference value for the highest level 
of maturation obtained in this model. By comparing the ratios of IFUs/GEs observed in 
IFN-γ treated cells to the reference value, we estimated the percentage of chlamydial 
particles during IFN-γ induced persistent infection that matured into infectious EB [(ratio 
in IFN-γ treated cells/ratio in untreated cells at 72 hai)x100]. During the IFN-γ induced 
persistent infection, 8% of C. pneumoniae genomes were in infectious particles at 72 h 
after inoculation, while approximately 90% of the particles did not maturate and/or they 
became inactivated. The level of successful maturation remained rather stable (up to 20 %) 
at 2 to 6 days after inoculation. 
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Microarray hybridization data of 4000 transcripts
Filter 1. >2-fold change in gene
expression in active infection or
in persistent infection or in cells
exposed to IFN-γ vs. untreated
control cells (Criterion 1, Table 6.).
250 gene transcripts
Filter 2. Different transcription
profile in active or persistent
infection vs. in cells exposed
to IFN-γ (Criteria 2-3, Table 6.).
73 gene transcripts
Filter 3. >2-fold change
in gene expression in 
persistent infection vs.
active infection
(Criterion 4,Table 6.)
29 gene transcripts
Publication (II)
Group 1: Gene transcripts 
altered  in more than one  study
condition (n=33)
Group 2: Gene transcripts
altered in only one study
condition (n=40)
A. Genes mainly
regulated by 
C. pneumoniae
(n=12)
B. Genes mainly
regulated 
by IFN-γ
(n=8)
C. Genes regulated 
by C. pneumoniae 
and IFN-γ
(n=13)
A. Genes 
regulated by 
C. pneumoniae
(n=5)
B. Genes
regulated 
by IFN-γ
(n=10)
C. Genes
regulated by 
C.pneumoniae
and IFN-γ (n=25)
Figure 4. Overview of the microarray analysis.
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Transmission electron microscopy identified a mixture of different types of inclusions in 
IFN-γ treated HL cells in agreement with earlier observations in IFN-γ induced persistent 
C. pneumoniae infection (Mathews et al., 2001, Pantoja et al., 2001). Small inclusions 
containing aberrant and large RB, small inclusions containing aberrant, pleomorphic RB 
normal in size, and small inclusions containing a mixture of mature-looking EB, 
intermediate forms and pleomorphic altered RB were observed (Figure 2/I). The major 
mechanism IFN-γ action on chlamydia is based on the induction of the host cell enzyme 
indoleamine 2,3-dioxygenase (IDO) involved in tryptophan catabolism (Mehta et al., 
1998). Pantoja et al. has suggested that tryptophan depletion affects more RB in their early 
stages and arrests them in a persistent state, and that the RB and EB at the later stages are 
less affected (Pantoja et al., 2001). This could explain why a mixture of different 
inclusions was observed in this study and by others when a low IFN-γ concentration was 
used (Mathews et al., 2001), whereas mainly inclusions typical for persistent infection are 
seen under higher IFN-γ concentrations (Pantoja et al., 2001). However, our data suggests 
that inclusions containing more mature-looking chlamydial developmental forms might 
also represent persistence, since no second cycle of infection could be detected by qPCR, 
passage, or staining of inclusions with fluorescein-labeled antibodies in these cultures. 
 
7.4. Host cell response to persistent C. pneumoniae infection in 
epithelial cells (II) 
 
Although Chlamydia multiplies in its own vacuole surrounded by the inclusion membrane, 
it is capable of interacting with its host cell and modulating host cell gene expression. This 
modulation requires chlamydial protein synthesis and it may assist the bacteria to establish 
persistence. In this study, we compared changes in host cell transcription of 4000 genes 
(available at that time) in response to productive and IFN-γ induced persistent C. 
pneumoniae infection in HL cells with cDNA array. To better understand the kinetics of 
the responses in active versus persistent C. pneumoniae infection models, changes in 
transcription profiles were studied at four time points between 6 hours and 6 days after 
infection. We established criteria to select host cell genes whose transcription was 
different between the studied conditions and we further analyzed the data to identify the 
genes specifically regulated in persistent C. pneumoniae infection and confirmed the 
results with RT-PCR analysis. Only the results focused on specific changes in persistent 
infection model at 6-48 hai and confirmed by RT-PCR analysis have been previously 
published. Although the microarray experiments were not repeated and therefore the 
results are only preliminary or suggestive, the screening results of the microarray data are 
presented here since the data on host cell responses to persistent Chlamydia infection is 
exiguous. Nevertheless, individual genes are only discussed if the observed response in 
transcription has been confirmed by another method. 
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When the same RNA preparations were studied by both microarray and RT-PCR (N = 21), 
approximately 70 % of the responses detected by microarray analysis could be confirmed 
by RT-PCR. In most unconfirmed cases the microarray analysis had obviously failed to 
detect a response to IFN-γ or to chlamydial infection at one time point. When the 
biological replicate samples were analyzed by RT-PCR, results of 43% of the genes 
correlated moderately well with the microarray results. In the context that others have 
reported RT-PCR validation percentages of 60-100% for microarray findings, our 
confirmation percentage by RT-PCR in biological replicate samples is somewhat low. One 
potential reason affecting the observed lower validation percentage is that in most reports 
up- or down-regulation of only one condition was studied, whereas in our study each of 
the studied conditions needed to correlate (also in magnitude) to microarray results in 
order to one gene transcript to be confirmed. Also, the inclusion of genes with low 
responses to RT-PCR confirmation based on their biological importance potentially 
affected the lower confirmation percentage. In addition, there was a considerable time lag 
between our microarray sample and biological replicate sample. Even though the different 
IFN-γ preparations used to induce persistent infection were carefully titrated and evaluated 
to ensure equal biological effect, it can not be excluded that the different preparations used 
might have had slightly different potencies.   
 
7.4.1. Initial analysis of the microarray screening 
 
The transcriptional responses of the HL cells in three different conditions were studied by 
a cDNA array: 1. Productive C. pneumoniae infection, 2. persistent C. pneumoniae 
infection induced by IFN-γ, and 3. IFN-γ treatment (to control the effect of IFN-γ alone on 
the gene transcription in HL cells). To confirm the nature of infection (active vs. 
persistent) in the used models, the number of infectious bacteria and GE present in 
cultures were quantified by their passage into permissive cell culture and qPCR, 
respectively. In the persistently infected cell cultures, < 3 % of the chlamydial particles 
were in infectious form at 3 days after infection when compared to the level reached 
during active infection. 
 
Initially three different selection criteria were used to extract significant results from the 
microarray data. First, genes with a significant change in relation to the untreated control 
cells were selected for each studied condition (criterion 1, Table 6.). Second, two-fold 
changes in the comparative analysis of the three samples representing different conditions 
were used to filter genes that had met the first criterion (criterion 2, Table 6.). Third, 1.5-
fold changes were selected among those genes that had met the first criterion in only one 
of the studied conditions but had not met the second criterion (criterion 3, Table 6.). 
Overview of the microarray analysis is presented in Figure 4. To confirm that the first 
criterion for a significant change in expression was sufficiently strict, and to control that 
vancomycin, an antibiotic used in the cell cultures, was not affecting HL cell transcription,  
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Table 6. Criteria used to filter the microarray data 
Criterion number Criterion equation 
Criterion 1 Mean of log2(sample/control) of the 3 replicate hybridizations ≥ 1 or ≤ -1, Coefficient of variation (CV) < 0.25 (25%). 
Criterion 2 
[(“acute infection” fold change /IFN-γ fold change) ≥ 2 OR ≤ 0.5] OR 
[(“persistent infection” fold change / IFN-g fold change) ≥ 2 OR ≤ 0.5],  in 
addition, at least the other fold change in the division equation has to fulfill 
criterion 1. 
Criterion 3 
If only one of the samples was fulfilling the criterion 1 (= sample x1), then 
[(sample x1 fold change/sample x2 fold change) OR (sample x1 fold 
change/sample x3 fold change)] ≥ 1.5 OR ≤ 0.67. 
Criterion 4  
(Criterion 2 in II) 
[(“persistent infection” fold change / “acute infection” fold change) ≥ 2 OR 
≤ 0.5]  AND [(“persistent infection” fold change / IFN-γ fold change) ≥ 2 
OR ≤ 0.5]  
 
RNA from HL cells grown in the presence of vancomycin was hybridized against RNA 
from HL cells grown without vancomycin on the microarray. When these data were 
analyzed using the above-mentioned criterion 1, a significant change was detected in the 
transcription level of 3 genes only.  Then, the RNA extracted from a pool of HL cell 
cultures grown with vancomycin was used as a hybridization control against which the 
transcription levels in studied samples were normalized. Of the approximately 4000 genes, 
250 genes initially fulfilled the criterion for a significant change in expression (criterion 1, 
Table 6.). Generally, the HL cell gene transcription was more often up-regulated than 
down-regulated upon infection with C. pneumoniae and treatment with IFN-γ. However, 
the IFN-γ treated culture at the latest time point studied (at 150 hpi) was an exception. At 
that time point the host cell gene expression, if altered, was mostly down-regulated. 
Interestingly, at the same time point the number of genes whose transcription was down-
regulated was lower in cells infected persistently with C. pneumoniae than in cells only 
treated with IFN-γ (Figure 5.). When the different conditions were compared, it was also 
noteworthy that at 48 hpi there were more up-regulated genes in the cells of the persistent 
infection model than together in the cells only infected with chlamydia or only treated 
with IFN-γ. At this time point, most of the C. pneumoniae RB forms have been 
transformed into infectious EB forms during the productive infection, whereas in the 
persistent nonproductive infection RB forms persist (Figure 5.). Similarly, in a study by 
Burian et al., C. trachomatis L2 infection of murine epithelial cells alone up-regulated 185 
genes, exposure to IFN-γ alone up-regulated 82 genes, and when combined, up-regulation 
of 503 genes was observed. A similar enhancing effect was observed for IFN-γ induced 
persistent infection of C. muridarum in murine epithelial cells, but it was less prominent 
(Burian et al., 2010).  
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Figure 5. General pattern of gene regulation in HL cells in response to 1. productive C. pneumoniae 
infection, 2. IFN-γ induced nonproductive C. pneumoniae infection and 3. IFN-γ. Cells were collected at 6, 
24, 48 and 150 h post infection (hpi), total RNA was isolated and hybridized against untreated HL cell pool 
(control) on a cDNA array containing 4000 genes. A two-fold change in transcription level of a gene in 
relation to control was considered up-regulation (A.) or down-regulation (B.). 
 
 
 
Comparative analysis of the C. pneumoniae and IFN-γ  effects on HL cell gene 
regulation 
The transcriptional profiles of the 250 genes that had fulfilled criterion 1 were then 
compared between the persistent and active infection models and the IFN-γ control. The 
73 genes that, in addition to meeting the criterion 1, fulfilled either criterion 2 or 3 were 
considered to have a different transcription profile in the active or persistent infection in 
comparison to the HL cells treated with IFN-γ. To further facilitate the management of the 
data, the genes were assigned to two groups. The 33 genes whose transcription was altered 
in more than one condition studied (criterion 1 was fulfilled in at least two conditions) 
were assigned to group 1. The 40 genes whose transcription was altered only in one of the 
studied conditions (criterion 1 was fulfilled only in one condition) were assigned to group 
2. Three subgroups were then formed inside each of these two main groups to facilitate 
comparisons of the different study conditions (Figure 6.). 
 
The genes whose transcription was mainly regulated by C. pneumoniae were assigned to 
subgroup 1 A. In this group the host cell transcriptional responses were usually stronger or 
lasted longer under the conditions representing persistent infection than in active infection. 
However, some genes, were similarly regulated both during active and persistent infection 
(Figure 6., 1A). The genes whose transcription was regulated by IFN-γ were assigned to 
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subgroup 1B. In this subgroup, consisting of IFN-γ regulated genes, the transcription was 
not directly regulated by C. pneumoniae alone, but still the responses of genes differed 
between the persistent infection model and the IFN-γ treatment. The up-regulation of 
transcription was in many cases seen earlier in the persistent infection model, and 
sometimes also stronger, than in the IFN-γ treated cells (Figure 6., 1B). The genes whose 
transcription was regulated by both C. pneumoniae and IFN-γ were assigned to subgroup 
1C. Among the genes assigned to this subgroup, regulation of the genes was seen in both 
C. pneumoniae infected and IFN-γ treated cells and when combined, in condition 2, the 
transcriptional changes were stronger, and in many cases, also the kinetics of the response 
was different. Toll-like receptor 4 (TLR4) induced core cluster of genes in human 
macrophages has recently been described (Nau et al., 2003). From the defined cluster of 
43 genes, 11 were present on the cDNA array used in this study. Seven of the 11 genes 
fulfilled criterion 1, and 4 out of the 7 genes were found to be differentially expressed 
between the studied conditions. All the 4 differentially transcribed genes, IFIT1 
(interferon-induced protein with tetratricopeptide repeats 1), IFITM1 (interferon induced 
transmembrane protein 1), ISG15 (15 kD interferon-stimulated protein) and PMAIP1 
(phorbol-12-myristate-13-acetate-induced protein 1.), fell into the subgroup 1C (Figure 6., 
1C). In agreement with our study, more potent up-regulation of many genes was observed 
upon IFN-γ induced persistent infection of C. trachomatis L2, and although less prominent 
also of C. muridarium, in murine epithelial cells. It was suggested that at least partially 
this enhancement effect may be due to the simultaneous switch-on of the TLR signaling 
pathway and IFN-γ receptor signaling pathway (Burian et al., 2010).  
 
The genes whose transcription was altered only by C. pneumoniae alone (condition 1) 
were assigned to subgroup 2A. The transcription of the genes assigned to this subgroup 
was significantly changed only upon productive C. pneumoniae infection. Four of the five 
changes specific for active infection were seen at 150 hpi. At this time point, C. 
pneumoniae is completing the second cycle of infection in these cells (Kuo and Grayston, 
1990, I). BCL2/adenovirus E1B 19kD-interacting protein 3 (BNIP3), which is involved in 
the induction of apoptosis (Chen et al., 1997), was up-regulated. The other up-regulated 
genes are involved in the metabolism. Also, down-regulation of the transcription of one 
gene was seen at 48 hpi (Figure 6., 2A). The genes whose transcription was altered only 
by IFN-γ were assigned to subgroup 2B. In the subgroup 2B, transcription of the genes 
was only changed upon IFN-γ treatment and again, the changes often appeared at the late 
time points. Both up-regulation and down-regulation of transcription was seen and these 
changes were absent in the persistent infection. This suggests that C. pneumoniae is able 
to counteract some of the responses induced by IFN-γ. For example, transcription of cell 
adhesion molecule ALCAM was specifically down-regulated and transcription of tumor 
protein p53 (TP53) was specifically up-regulated by IFN-γ (Figure 6., 2B). The specific 
down-regulation of ALCAM and up-regulation of TP53 at 150 hai in the IFN-γ control, 
but not in the persistent infection induced by IFN-γ was later also observed in an 
Affymetrix experiment (data not shown).  
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Figure 6. Tree views of genes differentially expressed in the three conditions studied (1. productive C. 
pneumoniae infection, 2. IFN-γ induced nonproductive C. pneumoniae infection and 3. IFN-γ). Group 1 
includes the genes, whose transcription was affected in more than one condition studied and group 2 
includes the genes, whose transcription was affected only in one condition studied. Each row represents 
normalized transcription level of a gene (the gene in question is indicated at the right side of a row) under 
one condition studied in relation to untreated HL cells: Red squares indicate up-regulation, green squares 
down-regulation and black squares unchanged transcription. The scale bar indicates fold difference in gene 
expression. The columns represent the time points 6, 24, 48 and 150 h post inoculation. 
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Furthermore, the ability of C. pneumoniae to overcome TP53 up-regulation was also 
shown by RT-PCR in the same samples as used in the cDNA microarray (Figure 7.) and 
also in biological replicate sample, although lesser amount of TP53 was produced in the 
replicate samples.Recently IFN-γ has been shown to induce TP53 expression also in 
human endothelial cells (Kim et al., 2009). The absence of p53 has been implicated to 
have a role in atherosclerosis acceleration by increasing cell proliferation (Guevara et al., 
1999). In view that C. pneumoniae is associated to lung cancer (Laurila et al., 1997, 
Littman et al., 2005) and TP53 is widely known as a suppressing factor for cancer, our 
finding that C. pneumoniae can antagonize IFN-γ induced up-regulation of TP53 in 
epithelial cells is intriguing. The genes whose transcription was altered only when cells 
were both inoculated with Chlamydia and exposed to IFN-γ were assigned to subgroup 
2C, forming the largest subgroup (Figure 6, 2C). In this subgroup, a significant change in 
transcription was detected only in the persistent infection. Up-regulation of several genes 
was seen at time points 6-48 hai. The genes assigned to this subgroup were heterogeneous 
in function, but more than half of the gene products have a function in apoptosis, in 
growth and proliferation, in immunity and inflammation, in signal transduction, or in 
transcription and translation.  
 
 
 
 
Figure 7. Real-time RT-PCR analysis of TP53 gene in sample preparations that were studied by microarray. 
In the model for active infection HL cells were inoculated with C. pneumoniae (1.), in the model for 
persistent infection HL cells were inoculated with C. pneumoniae and treated with IFN-γ (2.) and in a 
control for persistent infection HL cells were treated solely with IFN-γ (3.). Cells were harvested at 6, 24, 48 
and 150 h post inoculation (hpi). The relative expression levels are expressed as fold changes of a sample in 
relation to untreated HL cells. For expression levels obtained by the microarray (bars), a > two-fold change 
was considered significant, whereas for expression levels obtained by the RT-PCR (line), a > three-fold 
change was considered significant (see text). 
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7.4.2. Transcription analysis focused on genes differentially regulated in 
persistent infection and verification by RT-PCR 
 
After initial analysis the data analysis was focused on genes having ≥two-fold change in 
gene expression in persistent infection vs. active infection and IFN-γ treatment alone 
(criterion 4, Table 6.). After refiltering the data 29 genes (from subgroups 1A-C and 2C) 
were identified as having ≥two-fold change in gene expression in persistent infection vs. 
active infection and IFN-γ treatment alone. To verify this data, we employed Applied 
Biosystems TaqMan Gene Expression Assays to study expression of 28 genes using 
RNA extracted from the biological replicate samples. At each time point, cells collected 
from two different wells were analyzed by RT-PCR. After normalization to a 
housekeeping gene ACTB (β-actin), the mean difference in expression levels between two 
replicate cell preparations (28 genes, 3 time points, n=84) was 21% (median 15 %). In 
addition, the RNA preparations used in the microarray hybridization were used to study 
expression of 21 genes by real time RT-PCR. When the amount of ACTB mRNA was 
normalized to the amount of another housekeeping gene HSPCB (heat shock 90kD protein 
1, beta) mRNA in 48 biological replicate samples (including samples not analyzed in this 
study), a mean value of 2,48 (SEM=0,36) was obtained, but with 95% confidence interval 
the true mean lies between 1,76-3,2. This result and the normalization of the mRNA levels 
of studied samples to the levels of both housekeeping genes suggested that a 3-fold 
difference should be used as a cutoff for a significant difference detected by RT-PCR, 
although 2-fold differences could be distinguished using the standard curve.  
 
Of the 28 genes, verified by RT-PCR in biological replicate samples, the gene expression 
results of nine genes obtained by microarray and RT-PCR correlated well at all time 
points, and the changes observed in the expression of these nine genes were therefore 
considered to be specific for persistent C. pneumoniae infection. Of the nine genes, four 
have a function in immunity and inflammation related processes (IL7R, IFIT1, NMI and 
ISG15), two (FN1 and COL17A1) are adhesion-related and two play a role in growth and 
proliferation (IGFBP6 and CCND1). Interestingly, three of the genes involved in immune 
responses, IL7R, ISG15 and IFIT1, were also up-regulated in HeLa 229 cells infected with 
a C. trachomatis variant with nonfusing inclusions as compared to cells infected with a 
prototype strain of C. trachomatis D (Xia et al., 2005). The variant carries a mutated IncA 
gene and lacks IncA protein in the inclusion membrane (Suchland et al., 2000, Rockey et 
al., 2002). The IncA variant strain grows more slowly than the prototype strain and by 
inducing transcription of immune-related genes could lead to increased inflammation and 
pathogenicity (Xia et al., 2005). C. pneumoniae resembles the variant C. trachomatis in 
slow growth rate and low production of progeny, and the inclusions are not fusogenic. Yet 
C. pneumoniae encodes proteins localized to the inclusion membrane, including IncA, but 
the C. pneumoniae IncA shares only limited primary sequence homology with C. 
trachomatis IncA.  
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The up-regulation in persistent infection in comparison to active infection and IFN-γ 
control was most prominent for IGFBP6 (>500-fold up-regulation by RT-PCR), NMI and 
interleukin 7 receptor (IL7R) transcripts (Table 1./II). The IGFBP6 gene is involved in 
growth and proliferation. IGFBP6 belongs to a family of six insulin-like growth factor 
binding proteins that regulate IGF (insulin-like growth factor) activity, but can also have 
IGF independent actions (Firth and Baxter, 2002). Other members of the family, including 
IGFBP3, IGFBP5 as well as IGFBP6 were up-regulated upon L2 infection in monocytic 
cells (Ren et al., 2003) and HeLa 229 cells (Xia et al., 2003), but their potential role 
during infection has remained uninvestigated. IGFBP6 is considered anti-tumorigenic per 
se, however, in some cases, IGFBP-6 is associated with increased cancer cell 
tumorigenicity (Bach, 2005, Fu et al., 2010). IGFBP-6 is a rather specific inhibitor of 
IGF2 (Bach, 2005) and IGF2 has been reported to specifically enhance infectivity of C. 
pneumoniae in endothelial cells in vitro (Lin et al., 2001). The mechanism of enhancement 
by IGF2 has remained unknown, but it has been hypothesized that the simultaneous 
binding of chlamydial organisms and IGF-2 to the IGF2/M6P (mannose-6 phosphate) 
receptor may inhibit the uptake of lysosomal enzymes into endocytic vesicles, promoting 
the survival of C. pneumoniae in phagosomes (Lin et al., 2001). Two other ligands 
capable of binding to the IGF2/M6P receptor at separate binding sites, M6P and retinoic 
acid, have been reported to decrease infectivity of C. pneumoniae in endothelial cells 
(Puolakkainen et al., 2005). Increased expression of IGFBP6 could be a host’s attempt to 
limit infection of endothelial cells by inhibiting IGF2, although transmission of the 
infection from respiratory epithelium to endothelial cells of the vessel wall, via infected 
mononuclear cells may remain effective (Gieffers et al., 2004b). 
 
The persistent infection associated up-regulation of IL-7 receptor, a protein associated 
with both immune responses and human malignancies, was observed at 24 hai and 
according to RT-PCR analysis at 6 days after inoculation the transcription was still 
enhanced (data not shown). IL7R is a type 1 membrane glycoprotein and the functional 
receptor consists of two components, an alpha chain and a common gamma chain that is 
shared by the receptors for other cytokines (IL-2, 4, 7, 9, 15 and 21). IL-7 is needed for the 
development and proliferation of lymphocytes. A role for IL-7 mediated inflammation in 
atherogenesis has been suggested (Damås et al., 2003) and an increased serum level of IL-
7 has been found in patients with coronary heart diseases (Carratelli et al., 2006).  In a 
recent report by Konstantinidou et al. olive oil polyphenols were indicated to play a 
signiﬁcant role in the down-regulation of inflammatory genes including IL7R 
(Konstantinidou et al., 2010). The function of the IL-7R complex in epithelial tissues has 
remained unknown. However, up-regulation of IL7R in the respiratory epithelial cells 
might result in increased IL-7 signaling during C. pneumoniae infection. Bacterial 
invasion into intestinal epithelial cells has been shown to induce expression of IL7R that 
may, in turn, participate in the modulation of mucosal inflammation during infection 
(Yamada et al., 1997). In addition, IL-7 receptor signaling has been suggested to 
participate in the development of gastritis induced by Helicobacter (Ohana et al., 2001), a 
common cause of chronic gastritis and even gastric cancer. Whether IL-7 is actually 
56 
 
produced during persistent C. pneumoniae infection and could hence participate in the 
pathogenesis through interaction with its receptor, remains to be studied.  
Also, for a 15 kD interferon-stimulated protein (ISG15), IFIT1 and Cyclin D1 (CCND1), 
the observed up-regulation of transcripts in persistent infection was substantially stronger 
(more than 5-fold) than in the other conditions studied (Table 1./II). ISG15 is an 
interferon-stimulated, ubiquitin-like protein that becomes conjugated to cellular proteins 
(Ritchie and Zhang, 2004). ISG15 expression and conjugation to target proteins 
(ISGylation) is highly up-regulated by bacterial and viral infection as well as by LPS 
treatment (Kim and Zhang, 2003). ISG15 has antiviral effects in mice (Ritchie et al., 
2004), but unlike ubiquitination, ISGylation might not target proteins for degradation. 
Several ISG15 targets including both viral and host cell proteins have tentatively been 
identified (Giannakopoulos et al., 2005, Zhao et al., 2005, Skaug and Chen, 2010) 
including a number of cellular proteins associated with the cytoskeleton, e.g. cytokeratin 8 
(Loeb and Haas, 1994). Association of ISG15 with cytoskeleton filaments may exert 
antiviral activity by inhibiting binding of viral proteins to the cytoskeleton and therefore 
interfering with the assembly of viral particles (Loeb and Haas, 1994). The host cell 
cytoskeleton has also been suggested to play a role in chlamydial vacuole expansion, as a 
chlamydial secreted protease (CPAF) cleaves cytokeratin 8, potentially resulting in 
increased solubility of the host cell cytoskeleton (Dong et al., 2004). As CPAF is 
produced also during IFN-γ induced persistent infection (Heuer et al., 2003), it could be 
speculated that during persistent infection, ISGylation of host cell cytoskeleton together 
with at least partial inhibition of the CPAF translocation into cytoplasm could interfere 
with cytokeratin 8 cleavage by the chlamydial protease. This could affect the inclusion 
expansion and chlamydia release from host cells resulting in small inclusions and fewer 
infectious progeny during persistence.  
 
The CCND1 gene product plays a role in growth and cell proliferation. Up-regulation of 
CCND1 was sustained (still seen as late as 6 days after infection, Figure 5., also verified 
by RT-PCR, data not shown). To exert their biochemical functions, cyclins, including 
CCND1, form heterodimers with cyclin-dependent kinases (CDKs), but CCND1 also has 
CDK-independent properties (Fu et al., 2004). CCND1 promotes progression of the cell 
cycle and overexpression is associated with tumorgenesis, possibly due to the shortened 
time available for DNA repair during accelerated progression of the cell cycle (Stacey, 
2003). Whether cyclin D1 is a player in malignant transformation associated with 
chlamydial infections (Littman et al., 2005), remains to be elucidated.  
 
For COL17A1, a tissue type plasminogen activator (PLAT) and FN1, the observed up-
regulation of transcripts during persistent infection was less than 5-fold but more than 3–
fold higher than that observed in acute infection or in IFN-γ treated cells (Table 1./II). 
Fibronectin could contribute to the development of a sustained inflammatory response 
often accompanying chlamydial infection, as fibronectin 1 is a potential ligand of TLR4 
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(Okamura et al., 2001). A characteristic of diseased tissue both in atherosclerosis and 
asthma is an increased deposition of fibronectin and other structural molecules e.g. 
collagens in the extracellular matrix (ECM). It has been proposed that excess fibronectin 
deposition into the subepithelial space of the lung airways may contribute to the abnormal 
tissue remodelling and inhibit reepithelization in asthma (Hocking, 2002, Dolhnikoff et 
al., 2009) and fibronectin may be also an important regulator of vascular remodeling 
(Chiang et al., 2009). In addition, fibronectin can bind IL-7 in ECM and therefore may 
regulate the availability of IL-7 within the tissue microenvironment (Ariel et al., 1997). 
Increased expression of fibronectin could also result in modification of the bacterial 
surface and affect its pathogenic properties: host cell derived fibronectin has indeed been 
found in association with the surface of C. trachomatis EB (serovars D and L2) (Kleba et 
al., 2002), and could participate in the infectious process, although exogenous fibronectin 
did not alter the infectivity of C. trachomatis grown in fibronectin deficient cells (Kleba 
and Stephens, 2005). However, FN1 has been found to be slightly down-regulated in 
HeLa 299 cells upon C. trachomatis L2 infection (Xia et al., 2003).   
The genes identified here as specifically regulated upon persistent C. pneumoniae 
infection (IGFBP6, NMI, FN1, CCND1, COL 17A1, ISG15, IFIT 1, PLAT, and IL7R) 
had not previously been reported to change upon C. pneumoniae infection. Although 
shortly after the up-regulation of ISG15 and IFIT1 were also observed in IFN-γ induced 
persistent C. pneumoniae infection (Eickhoff et al., 2007). Quite recently, in a study by 
Burian et al. more potent up regulation of IFIT1, NMI, and PLAT was observed in IFN-γ 
induced persistent infection of C. trachomatis L2 in murine epithelial cells (Burian et al., 
2010). Infection of HeLa 229 cells with C. trachomatis has been reported to up-regulate 
transcription of IGFBP6, ISG15 (also known as G1P2), and IFIT1, and to down-regulate 
that of FN1 (Xia et al., 2003, Lad et al., 2005), although also up-regulation have been 
observed (Burian et al., 2010). Microarray analysis of C. trachomatis L2 infected THP-1 
cells has shown up-regulated transcription of ISG15 and IFIT1 (Ren et al., 2003). Since 
the altered mRNA profiles may not reflect altered production of corresponding proteins 
(Gygi et al., 1999), additional techniques, such as Western blot analysis, are needed to 
support the findings in this study. 
 
7.4.3. Other microarray studies on host cell transcription in persistent C. 
pneumoniae infection  
 
Presently, there is only one other published study that has used microarray technology to 
screen host cell changes upon persistent C. pneumoniae infection of epithelial cells 
(Eickhoff et al., 2007). They used Affymetrix human genome U133A chips to study IFN-γ 
induced persistent infection of C. pneumoniae CWL-029 in an epithelial cell line (HeLa). 
They produced samples for two independent microarray experiments at 24 hours after 
infection for both active and persistent C. pneumoniae infection and an additional sample 
at 96 h after infection for persistent infection. Hybridization intensities of host cell 
transcripts in infected cultures were compared to those of mock infected cultures to create 
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fold changes. The mock infected culture of persistent infection contained IFN-γ to subtract 
responses created solely by IFN-γ. Fiftyseven genes were identified as differentially 
regulated by C. pneumoniae, 19 genes were selected for RT-PCR analysis, and responses 
of 17 genes could be verified (Eickhoff et al., 2007). Of the 57 genes identified by 
Eickhoff et al. 27 gene sequences were present on the cDNA array used in our study and 
only seven of the genes were here identified as differently regulated upon C. pneumoniae 
and/or IFN-γ induced persistent C. pneumoniae infection (Table 7.). Six of the genes had 
similar responses in both studies and one gene (BNIP3) was identified as down-regulated 
in all studied conditions by Eickhoff et al., while we found up-regulation of this transcript 
at 150 h after infection by active infection but not by persistent infection (unverified 
observation). However, slight down-regulation of BNIP3 was also seen in our experiment 
in C. pneumoniae infected samples at 6-48 hai, although it did not fulfill our criteria for a 
significant change. Of the nine genes identified as specifically up-regulated by microarray 
and RT-PCR in independent samples of persistent C. pneumoniae infection in our study, 
only two genes were identified by Affymetrix, which contains probe sets for all nine 
genes, in the study by Eickhoff et al. indicating moderately low agreement between the 
studies. This may be due to different C. pneumoniae isolates used, different MOI used for 
infection (30 vs. 0.5), different amount of IFN-γ used to induce persistence (100 U vs. 25 
U) and different cell lines used in the studies. The transcription kinetics may also be 
different as already seen in the similar gene responses between the studies (Table 7.). The 
differences may also be due to technical reasons relating to microarray technology. Thus, 
more studies on host cell transcription during persistent C. pneumoniae infection are 
needed in order to identify the genes involved in the interactomics of persistent C. 
pneumoniae infection. However, there were also similarities between the studies. In 
agreement with our study, Eickhoff et al. observed longer lasting up- or down-regulation 
of gene transcripts in persistent C. pneumoniae infection in comparison to active infection. 
They also showed that some of the responses were due to bacterial metabolism, since 
several responses were absent when rifampin was introduced to cultures directly after 
infection (Eickhoff et al., 2007). Supporting this observation, in our study most 
differences in transcription between persistent and active infection were observed at 48 h 
after infection, when most of the metabolically active RB-forms are transformed into EB-
forms in active infection. The longer lasting up or down regulations of genes observed in 
the studies may also be due to continuing bacterial metabolism in the cultures of persistent 
infection.  
59 
 
 
Table 7.  C
om
parison of the tw
o published m
icroarray studies on IFN
-γ  induced persistent infection of epithelial cells (Eickhof et al., 2007 and II). Results from
 II are presented w
ith gray background.
6h C
pn
6h C
pn + IFN
-γ
24h C
pn
24 h C
pn
24h C
pn+IFN
-γ
24 h  C
pn + IFN
-γ
48 h C
pn
48 h C
pn + IFN
-γ
96h C
pn+IFN
-γ
150h C
pn
150h C
pn + IFN
-γ
dual specificity phosphatase 6 
(D
U
SP6)
208892_s_at
BC
003143.1
N
C
N
C
I 
N
C
N
C
N
C
N
C
I
N
C
N
C
N
C
follistatin (FST)
204948_s_at
N
M
_013409.1
N
C
N
C
I
N
C
I
N
C
N
C
I
N
C
N
C
N
C
FO
S-like antigen 1 (FO
SL1)
204420_at
N
M
_005438
I
I
I
I
I 
I
N
C
I
N
C
N
C
N
C
H
om
o sapiens BC
L2 
adenovirus E1B 19kD
-
interacting protein 3 (BN
IP3)
201848_s_at
N
M
_004052
N
C
N
C
D
N
C
N
C
N
C
N
C
N
C
D
I
N
C
221478_at
N
M
_004052
D
D
D
H
um
an connective tissue 
grow
th factor (C
TG
F)
209101_at
M
92934.1 
I
I
I
I
N
C
I
N
C
N
C
N
C
N
C
N
C
interferon-induced protein 
w
ith tetratricopeptide repeats 
1 (IFIT1)
203153_at
N
M
_001548.1
N
C
N
C
N
C
I
I 
I
I
N
C
I 
N
C
N
C
interferon-stim
ulated protein, 
15 kD
a (ISG
15)
205483_s_at
N
M
_005101.1 
N
C
N
C
I 
I
I
N
C
I
I
N
C
N
C
N
C
a from
 experim
ent by Eickhof et al. 2007; h = tim
e point after infection; C
pn = active C
. pneum
oniae infection; C
pn + IFN
-g = persistent C
. pneum
oniae infection; D
= decrease in transcripts; I= increase in transcripts; N
C
= no change 
  G
ene
A
ffym
etrix 
probe set a
A
ccession 
N
um
ber
C
hange in transcription 
60 
 
7.5. C. pneumoniae infection model in a monocytic cell line (I) 
 
In addition to providing possible means of transport out of the lungs to other anatomical 
sites, infection of monocytes/macrophages with C. pneumoniae affects the adherence and 
migration properties of the macrophages, potentially leading to enhanced accumulation of 
macrophages in atherosclerotic plaques. To mimic infection of macrophages in vivo, we 
set up a C. pneumoniae infection model in the Mono Mac 6 cell line, which is a 
macrophage-like cell line that expresses phenotypic and functional properties of mature 
monocytes. We characterized the growth of the C. pneumoniae K6 isolate in the Mono 
Mac 6 cell line in the presence and absence of IFN-γ  by qPCR, infectivity assay, and 
microscopy. A growth curve of C. pneumoniae in Mono Mac 6 cell line showed a 
decrease in the number of infectious EB immediately after inoculation and at 12 h post 
infection. After that the number of EB increased clearly up to 48 h after infection 
suggesting that most differentiation of EB into RB took place between 36-48 h after 
infection. Unlike in HL cells, the amount of infectious C. pneumoniae cultivable from 
Mono Mac 6 cells remained rather stable up to 192 h post infection and no evidence of a 
second infectious cycle of C. pneumoniae in the Mono Mac 6 cells was observed (Figure 
3./I). 
 
The number of GE decreased during the first 12 h after inoculation and the C. pneumoniae 
genomes accumulated between 12-48 h after inoculation in the Mono Mac 6 cells. At later 
time points, the number of C. pneumoniae GE remained at a rather stable level during the 
observation period of 8 days (Figure 3./I). The doubling time of C. pneumoniae genomes 
in Mono Mac 6 cells (10-14 h) was found to be much longer than that of in HL cells (6-7 
h). However, in Mono Mac 6 cultures infected with heat and UV-inactivated C. 
pneumoniae a significant portion of DNA detected in cells immediately after inoculation 
still persisted at 72 hours post infection, which may interfere with the results. By TEM 
inclusions containing a mixture of RB, intermediate, and EB forms could be detected 72 
hours post infection in the untreated cultures. As observed earlier by others (Koehler et al., 
1997, Airenne et al., 1999), we found many RB forms in monocytic cell line that exhibited 
pleomorphic morphology (Figure 2./I). 
  
The effect of IFN-γ on C. pneumoniae growth in Mono Mac 6 cells was followed after 
treating the cells with increasing concentrations of IFN-γ. A concentration of 1000 U/ml 
was chosen for further experiments, since it was the lowest concentration that had an 
effect on inclusion morphology and infectivity of C. pneumoniae. In the presence of 1000 
U/ml of IFN-γ, the number of infectious particles recovered from the infected cells 
decreased initially, and increased a little at 36 – 48 h post infection. However, after 72 
hours post infection the number of EB decreased and no C. pneumoniae could be cultured 
at 168 hours post infection. The C. pneumoniae genomes decreased during the first 12 h 
after inoculation, increased slightly at 12-36 h post infection suggesting that C. 
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pneumoniae DNA was replicated during this period, after which the number of genomes 
decreased and stayed at a rather stable level to the end of the observation period (Figure 
3./I). 
 
Human macrophages are able to support the growth of C. pneumoniae (Godzik et al., 
1995), although the burst size of infection is low, suggesting that macrophages can to 
some extent naturally restrict the growth of C. pneumoniae. Chlamydia infection of 
monocytes resembles persistent infection with minimal bacterial cell division and with a 
low level of infectious progeny. In our experment, a relatively high concentration of IFN-γ 
(1000 U/ml) was needed to further restrict the growth of C. pneumoniae in human 
monocytic cell line. With this IFN-γ concentration, C. pneumoniae genomes were still 
detectable and remained at a rather stable level, although the cultures did not produce 
infectious EB. Also, Airenne et al. (Airenne et al., 1999) have suggested that human 
monocyte-derived macrophages require a higher concentration of IFN-γ than epithelial 
cells to suppress production of infectious progeny. However, even under these conditions, 
C. pneumoniae still stays viable, since C. pneumoniae transcripts can be detected in IFN-γ 
treated cultures still at 8 days after infection. 
 
7.6. Transcription of selected genes in C. pneumoniae infection of 
monocytes (III) 
 
Immune cells offer an important link between the initial site of C. pneumoniae infection 
and the chronic inflammatory disease. The infection of the Mono Mac 6 cell line without 
the IFN-γ exposure may represent a persistent infection per se, since the level of infectious 
progeny in relation to the detected number of chlamydial genomes is low. However, the 
IFN-γ exposure further restricts chlamydial growth and C. pneumoniae is known to elicit 
an IFN-γ response in vivo. In addition, as IFN-γ exposure is known to affect the 
transcription of C. pneumoniae genes in epithelial cells, we decided to study the 
transcription of C. pneumoniae genes both in the presence and the absence of IFN-γ in the 
monocytic cell culture 
 
The transcription of 11 C. pneumoniae genes in Mono Mac 6 cells were analyzed during 
infection by real time RT-PCR. Our primary interest was to study the secreted genes 
(incA, cpaf, cpn0572, cpn0809 and lcrE) and the genes (ompA, omp2, ftsK, euo, htrA and 
hsp60) that were previously found differentially expressed in persistent infection models 
in epithelial cell lines. To control the C. pneumoniae infection in the monocyte - 
macrophage cell culture model, C. pneumoniae genomes, 16S rRNA -transcripts and 
Mono Mac 6 cell concentration were measured quantitatively from all three individual 
experiments. In addition, the viability of C. pneumoniae in Mono Mac 6 cells was 
analyzed by passaging the samples into permissive cells (HL) to measure recovery of live 
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bacteria (inclusion forming units, IFUs). The growth of C. pneumoniae in IFN-γ exposed 
and unexposed cultures was found to be similar to our previous study (I).  
 
Samples from infected and infected and IFN-γ treated Mono Mac 6 cells were collected at 
6, 36, and 72 hours after infection in three independent experiments and analyzed by real 
time RT-PCR. According to the observed transcription kinetics, the 11 analyzed genes 
were divided into 4 groups: I. early-cycle genes: the transcripts were abundant already at 6 
hours after infection and decreased between 6 and 36 hours after infection, II. mid-cycle 
genes: the accumulation of transcripts was most abundant between 6 and 36 hours after 
infection, representing the metabolically most active stage when chlamydial genomes 
replicate and cells divide (I), III. late-cycle genes: the number of transcripts was 
increasing between 36 and 72 hours after infection during the late developmental stage of 
C. pneumoniae, when the RB forms are transforming into the EB forms in Mono Mac 6 
cells (I), and IV. Constitutively expressed genes (Table 2./III).  
 
The 16SrRNA normalized transcription levels of the studied C. pneumoniae genes tended 
to be slightly lower in the IFN-γ exposed monocyte cultures for most of the studied genes 
at 72 hours after infection. However, statistically significant differences in the 
transcription levels between IFN-γ exposed and unexposed cultures were observed only 
for omp2 and cpaf transcripts (Table 2./III).  The kinetics of transcription of most of the 
11 studied genes was similar in both conditions, with only the transcription of incA and 
euo being exceptions. This finding is in contrast to the earlier reports on C. pneumoniae 
transcription in persistent infection of epithelial cells, whereas also Airenne et al. reported 
that IFN-γ had no significant effect on C. pneumoniae mRNA (omp2 and hsp60) levels in 
infected PBMC (Airenne et al., 1999, Hogan et al., 2004). 
 
7.6.1. Early cycle genes 
 
In consistence with the previous studies in fibroblasts and epithelial cells (Wichlan and 
Hatch, 1993, Shaw et al., 2000, Belland et al., 2003a) the C. pneumoniae euo gene was 
identified to have an early-cycle transcription profile (group I). When the cultures were 
exposed to IFN-γ, the transcription profile of the euo gene resembled constitutive 
expression (Table 2./III). The Euo protein, which is capable to bind DNA in vitro, has 
been suggested to have a role in chlamydial chromosome decondensation early in the 
infection by degrading the histone like protein Hc1 (Kaul et al., 1997, Zhang et al., 1998). 
Hence, it is likely that Euo has a role in transcription regulation. In some studies, euo 
transcription has been up-regulated in the persistent infection model (Ouellette et al., 
2006, Timms et al., 2009). However, also no change in the transcription or even down-
regulation of the euo transcript during the persistent C. pneumoniae infection have been 
reported (Mäurer et al., 2007, Timms et al., 2009). 
63 
 
7.6.2. Mid-cycle genes 
 
Transcription profiles of C. pneumoniae genes ompA and htrA were identified as mid-
cycle genes in mononuclear cells and thus were assigned to group II (Table 2./III). The 
observed transcription profile is in consistence with earlier reports on ompA transcription 
in epithelial cells (Hogan et al., 2003, Nicholson et al., 2003). There was no difference in 
the transcription of the ompA gene either between the IFN-γ exposed and unexposed 
monocyte cultures, or between the infected monocytes and epithelial cells, suggesting a 
similar transcription profile in both cell types. Both up-regulation and down-regulation of 
C. pneumoniae MOMP expression have been reported in persistent infection models 
(Timms et al., 2009, Hogan et al., 2003, Mathews et al., 2001). Up-regulation of htrA 
transcription and translation have been reported in both IFN-γ and iron depletion induced 
persistent models of C. pneumoniae infection in epithelial cells (Mukhopadhyay et al., 
2006, Polkinghorne et al., 2006, Mäurer et al., 2007, Timms et al., 2009). Also, here htrA 
was up-regulated in the mid-cycle (group II), whereas the kinetics of transcription during 
the infection of the HL control cultures showed up-regulation only after exposure to IFN-
γ. The expression of htrA seems to be consistently up-regulated during persistence, which 
makes it a potential biomarker of persistent Chlamydia infection. 
 
In addition, the transcription of incA and cpaf genes followed the profile of the mid-cycle 
genes when the cells were grown in IFN-γ exposed cultures. The transcription of the C. 
pneumoniae cpaf gene was similar also in bacteria grown without IFN-γ, but no statistical 
difference was found for the transcript accumulation between 6 and 36 hours after 
infection (Table 2./ III). IncA protein seems to play role in inclusion fusion during C. 
trachomatis growth and it may also prevent fusion of chlamydial endosome/inclusion and 
lysosomes. In addition, IncA may play an important role in obtaining nutrients into the 
host cell (Paumet et al., 2009, Wyrick, 2000, Hackstadt et al., 1997, 1999) and in the 
study by Slepenkin et al, incA was not expressed in cultures exposed to a T3S inhibitor 
(Slepenkin et al., 2007). In monocytes exposed to IFN-γ, the transcription of incA was up-
regulated during the developmental cycle. In contrast to the unexposed cultures, the 
highest level of incA transcript was observed in the middle of the developmental cycle (at 
36 hpi) when the RB are converting into the EB. Interestingly, Matthews and co-workers 
found another inclusion membrane protein, cpn0585, which resembles C. psittaci incA, to 
be up-regulated in a model of persistent infection and speculated that the up-regulation is a 
mechanism for C. pneumoniae to modulate its survival in stressful conditions such as in 
the IFN-γ induced persistence or during infection of macrophages (Mathews et al., 2001). 
By immunofluorescence microscopy we showed that the IncA protein is also produced 
and localizes to the chlamydial inclusion membrane during infection as reported earlier for 
C. pneumoniae infection in epithelial cells (Bannantine et al., 2000), suggesting that the 
T3S apparatus is functional also during C. pneumoniae infection in monocytes. Upon IFN-
γ exposure, IncA protein could also be stained, but the staining pattern appeared more 
often granular (Figure 2., A and B/ III).   
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Also, transcription of the chlamydial proteasome-like activity factor CPAF gene was 
found to be up-regulated in the mid cycle. In addition, a statistically significant difference 
was noted at 72 hai in the normalized transcription levels between IFN-γ treated and 
untreated cultures, the transcription level being lower in the IFN-γ exposed cultures. Heuer 
et al. have previously shown by immunofluorescence microscopy that CPAF is expressed 
in C. pneumoniae infected epithelial cells at 1-2 day post infection (dpi), but remains in 
the inclusion until 3 dpi after which it is translocated into the host cell cytosol (Heuer et 
al., 2003). However, in persistent C. pneumoniae infection models CPAF has been shown 
to be produced, but the transport of the protein into host cell cytosol is at least partially 
inhibited (Heuer et al., 2003). In our model, the immunofluorescence staining of CPAF 
protein was predominantly in inclusions at 72 hour post infection, and both inclusions and 
the host cell cytosol were stained at 96 hour post infection suggesting partial secretion into 
the host cell cytosol (Figure 2 C and D/III). The host cell cytoskeleton, a network of 
microtubules, actin filaments, and intermediate filaments (IF), are implicated to be 
involved in chlamydial entry, inclusion expansion, and exit. In addition to cleaving host 
cell transcription factors, CPAF has been shown to be capable of also cleaving host cell 
IF-proteins cytokeratin 8, cytokeratin 18, and vimentin (Heurer et al., 2003, Dong et al., 
2004, Kumar and Valdivia, 2008). A possible outcome of CPAF cleaving activity of IF is 
to make the cytoskeletal structures surrounding the chlamydial inclusion more flexible and 
allow expansion of the inclusion during the developmental cycle (Kumar and Valdivia, 
2008). The observed down-regulation of CPAF transcription in monocytic cell line when 
exposed to IFN-γ may affect the ability of C. pneumoniae inclusion to expand, explaining 
in part why normal inclusions are not observed in these cells.  
 
7.6.3. Late-cycle genes  
 
The late transcription profile was observed for omp2, lcrE, cpn0572, and cpn0809. 
Although no statistically significant changes could be detected for lcrE transcription, the 
gene was assigned to the group III, since the transcripts were absent (at 6 hai) or at very 
low level (at 36 hai) before 72 hours after infection. Accumulation of the cpn0572 
transcripts was statistically significantly increased between 36-72 hours after infection for 
cultures without IFN-γ, and the transcription profile in the IFN-γ exposed cultures was 
rather similar, but did not reach statistical significance (Table 2./III).  Transcription of the 
cpn0572, which encodes a C. pneumoniae TARP homolog is a putative T3S-effector 
protein and it has been suggested to play a role in chlamydial entry into the host cells by 
recruiting actin at the entry site (Clifton et al., 2004). The observed late transcription 
profile is consistent with the finding by Mäurer and co-workers, that the TARP protein is 
present in the EB (Mäurer et al., 2007). Also the transcription of another putative T3S 
substrate, the cpn0809, was induced late in the developmental cycle both in the IFN-γ 
exposed and unexposed cultures, as has been described earlier in epithelial cells (Mäurer 
et al., 2007, Lugert et al., 2004). The late transcription profile combined with the 
localization of the protein to the host cell cytosol suggests that it may have a role in the 
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exit of Chlamydia from the host cell. The transcription of lcrE, a component of the T3S, 
was rather stable in our study, although it has been shown to be down-regulated in 
persistent C. pneumoniae infection models of epithelial cells (Mäurer et al., 2007, 
Slepenkin et al., 2003). Like its homolog YopN in Yersinia, LcrE of C. pneumoniae may 
regulate the release of T3S effector proteins by controlling their access to the secretory 
channel. In a recent report by Huang et al., LcrE was described to modify the host cell 
microtubule network and in “functional LcrE knock outs” C. pneumoniae replication was 
inhibited in a dose dependent manner, suggesting an essential role for the LcrE protein in 
C. pneumoniae development (Huang et al., 2008). 
 
The transcription of the chlamydial membrane protein gene omp2, was assessed in this 
study. In agreement with previous studies performed in epithelial cells (Watson et al., 
1995, Hogan et al., 2003, Nicholson et al., 2003), the transcription of omp2 was induced 
in the late cycle. On the contrary, the transcription of the omp2 gene was found to be 
significantly down regulated in the IFN-γ exposed monocyte cultures. Our finding is in 
agreement with an earlier report, in which, using murine alveolar macrophages, Haranaga 
et al. found that the omp2 transcripts were attenuated late in the developmental cycle (at 
36-48 hpi) (Haranaga et al., 2003). The Omp2 protein has been suggested to have a role in 
the RB to EB differentiation (Watson et al., 1995). In our infection model, more infectious 
EB were formed in the absence of IFN-γ, whereas the reduced production of omp2 mRNA 
could well be related to the absence of infectious progeny (I) in the IFN-γ exposed 
monocyte cultures. Omp2 has been suggested to be repressed by the Euo protein during 
the active growth phase of chlamydiae (Zhang et al., 1998) and Belland et al. suggested 
that elevated expression of Euo protein during IFN-γ induced persistent C. trachomatis 
infection in epithelial cells contributes towards silencing of the late gene expression in 
persistence (Belland et al., 2003b). Despite the rather stable transcription of the euo gene 
observed in this study, omp2 transcription was down-regulated in the IFN-γ exposed 
cultures. This suggests that additional regulatory elements exist for omp2 transcription.  
 
7.6.4. Constitutively expressed genes 
 
For two genes, ftsK and hsp60, no significant differences in the transcript levels were 
noted during the observation period. Therefore, the genes were assigned to group IV of 
constitutive expression (Table 2./III). The observed low level of constitutive expression of 
ftsK, whose product is required for chlamydial cell division, supports the hypothesis that 
infection in monocytes resembles persistent infection with minimal bacterial cell division. 
The ftsK is often down-regulated in epithelial cells exposed to IFN-γ or upon iron 
depletion (Byrne et al., 2001, Slepenkin et al., 2003, Polkinghorne et al., 2006, Timms et 
al., 2009).  
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The expression of Hsp60 has been extensively studied in various models of persistent 
infection without a uniform outcome (Matthews et al., 2001, Slepenkin et al., 2003, 
Polkinghorne et al., 2006, Ouellette et al., 2006, Mäurer et al., 2007). Also, in monocyte 
cultures, both up-regulation and down-regulation of hsp60 mRNA have been reported 
(Airenne et al., 1999, Haranaga et al., 2003, Gieffers et al., 2001). In our study, a rather 
stable (constitutive) expression of hsp60 was observed both in the presence and absence of 
IFN-γ. Taken together, this suggests that up-regulation of hsp60 during the persistent stage 
of C. pneumoniae infection is not as marked as in C. trachomatis infection (Hogan et al., 
2004). However, Beatty et al. speculated that direct control at the translational level may 
explain increased chlamydial hsp60 to MOMP ratio in IFN-γ induced C. trachomatis 
infection, since MOMP, but not Hsp60, contain significant number of tryptophan residues 
(Beatty et al., 1994c). This kind of direct regulation would yield increased hsp60 to 
MOMP ratio also in IFN-γ induced persistent C. pneumoniae infection in epithelial cells, 
since C. pneumoniae MOMP contains 10 tryptophan residues whereas Hsp60 contains 
none (as determined from C. pneumoniae Tw183, Swiss-Prot IDprotien sequence: 
MOMP, P27455; Hsp60, P31681).  
 
Our results suggest that the transcriptional profile of the studied genes in monocytes is 
different from that seen in epithelial cells and that IFN-γ exposure affects less C. 
pneumoniae transcription in monocytes in genes studied. Furthermore, our study shows 
that genes related to bacterial secretion are transcribed and IncA and CPAF proteins are 
produced. The detection of IncA protein in the inclusion membrane suggests that T3SS is 
fully functional during C. pneumoniae infection in monocytes.  
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8. CONCLUSIONS AND FUTURE PROSPECTS 
 
Interactions between Chlamydia and its host may have several outcomes. These 
interactions may lead to a mild or asymptomatic infection which is followed by successful 
eradication of the pathogen or to longer relationship between the pathogen and its host 
potentially leading to sustained inflammation and tissue damage. This longer relationship 
with the host, termed persistence, is characterized in chlamydial infection by presence of 
abnormal RB unable to divide. The molecular details of host–pathogen interaction that 
support persistence are still largely unknown, but such interactions have been mostly 
studied in the cell culture models for persistent Chlamydia infection.  Even though the 
aberrant RB morphology of persistent C. pneumoniae appears similar in all in vitro 
models the transcription profile is dependent on the means by which persistence is induced 
(Klos et al., 2009, Timms et al., 2009). However, there are a few genes showing 
consistent regulation across the used models, including the htrA gene. It has been shown 
to be up-regulated in the IFN-γ and iron depletion induced persistent infection in epithelial 
cells, and now also during C. pneumoniae infection of monocytes (III). Hence, HtrA has 
potential as a biomarker of a persistent C. pneumoniae infection and its usefulness in 
diagnostic applications should be further studied, since currently there is no reliable 
method to identify chronic C. pneumoniae infection in vivo.  
 
Common antibiotic agents have proved inefficient in eradication of persistent chlamydial 
infection and circulating monocytes carrying C. pneumoniae may also have reduced 
antibiotic susceptibility. Hence, there is a need for new methods and compounds effective 
against persistent Chlamydia infection and against the spreading of Chlamydia from lungs 
to other tissues. In this study, we observed that the IncA protein is translated and localized 
into the inclusion membrane suggesting the presence of a functional T3S during infection 
of monocytes. Since small molecule inhibitors of T3S are able block C. pneumoniae 
growth in epithelial cells (Slepenkin et al., 2007, Bailey et al., 2007), testing whether the 
use of small inhibitory molecules targeting the T3S during infection of monocytes could 
lead to the development of novel treatment to chronic chlamydial infection is warranted 
(III). Successful treatment of C. pneumoniae residing in monocytes could also potentially 
prevent spreading of the organisim from the initial site of the infection.  
 
In addition to elucidating molecular mechanisms of persistent Chlamydia infection, 
analysis of host cell transcriptome during persistence may also reveal new targets for 
therapeutic interventions or diagnostic applications. This study involved investigation of 
host cell responses in the persistent C. pneumoniae infection by microarray. The results 
revealed several previously unknown alterations of host gene expression induced by C. 
pneumoniae which provide new targets for further analysis of their role in this particular 
host-pathogen interaction. Some responses in the host cell gene expression were specific 
for persistent infection and some responses were potentiated in the persistent infection 
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perhaps through overlapping pathways of TLR4 and IFN-γ. These responses, if also 
occurring at the protein level, are likely to have an impact in chlamydial infection or in 
chlamydial disease. Another important finding of the present study was that some 
responses induced by IFN-γ were absent in persistent infection. Especially the ability of C. 
pneumoniae to overcome up-regulation of the TP53 gene might be important. Further 
studies are required to evaluate the significance of the genes identified in the present 
study. However, the results obtained from this microarray study will provide a basis for 
the elucidation of selected genes and pathways for the host response in productive and 
persistent C. pneumoniae infection (II). Although the host cell transcriptome during 
persistence is at present only studied in the IFN-γ model, it is likely that also the host cell 
responses are dependent on the stimulus of which persistent state is achieved. On the other 
hand, they may overlap and provide universal markers of persistent C. pneumoniae 
infection. However, if such markers are not found among bacteria or the host genes, 
identification of gene and protein expression patterns representing persistent infection 
would also allow development of diagnostic applications. 
 
Host cell responses and host-pathogen interactions in persistent C. pneumoniae infection 
are still to a large degree unraveled. Studies focusing on the molecular interactions of 
Chlamydia and its host during persistent infection should be the primary interest of future 
studies in both cell culture and experimental models as well as in vivo. In future 
investigations on parallel kinetic analysis of host and Chlamydia transcriptome and 
proteome from the same samples would allow for correlating the expression of chlamydial 
genes with effects on the host. Relevance of the identified host cell genes or pathways can 
be further studied by RNAi, whereas relevance of both the identified chlamydial and host 
cell genes can be studied by overexpressing the protein during active C. pneumoniae 
infection. Interactions of the identified proteins can also be studied by yeast two-hybrid 
system or protein arrays. Since these methods complement each other combined use is 
beneficial. A major challenge of the future is to convert these model systems to clinical 
reality in form of new diagnostic methods and therapy of chronic C. pneumoniae 
infection.  
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